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The physiological effects of single and multiday road running races have been studied extensively 
and  include the occurrence of rhabdomyolysis, reflected by significantly increased urinary 
myoglobin (uMb), as well as increased concentrations of serum  creatine phosphokinase (CPK),  
high sensitivity C-reactive protein (hsCRP),  cortisol and cardiac troponin-T (cTnT), dehydration 
and compromised renal function.  Furthermore, in hyperthermic athletes, a positive relationship 
has been noted between hyperthermia, muscle damage, dehydration and pacing.  The 
physiological effects of a multiday trail run of similar duration to single day road races, however, 
are unknown.  
 
The side-effects of the use of statin medication for hypercholesterolaemia include muscle fatigue, 
cramping and increased muscle damage. These have been found to be aggravated in endurance 
athletes and it has been reported that females, especially when being medicated from a young age, 
are more susceptible to these side-effects.      
 
Objectives 
1.  To investigate the effect of a three-day trail run on systemic and urinary markers of muscle 
damage and inflammation in recreational runners and to establish the association of dehydration 
and hyperthermia with these markers. 
2. To observe the effect of the three day trail run on systemic and urinary markers of muscle 
damage and inflammation on an additional hypercholesterolaemic female athlete using statin 
medication in combination with a lipid uptake inhibitor. 
 
Method  
Firstly, an observational cohort study was conducted on 19 recreational male (n=6)  and female 
(n=13)  athletes during a 95km trail run over three days. 
 
Pre-and post-stage and 24 and 72 h post-race concentrations of  serum CPK, hsCRP, cortisol, 
cTnT, and osmolality (sOsm) as well as uMb, changes in body mass, delayed onset muscle 
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soreness (DOMS) and thigh circumference (TC) were measured. Continuous recordings of heart 
rate (HR) and intestinal temperature (Tintest ) were made  throughout each stage. 
 
In addition, a case report is included on one trained female endurance athlete currently being 
treated for familial hypercholesterolaemia with 20 mg Aspavor and 10 mg Ezetrol daily and not 
included in the above cohort, to investigate the degree of muscle damage and inflammation she 
experienced as a result of participation in the three-day event. 
 
Results:   
Heart rate ranged between 77 and 83% age-predicted-maximum (APmax) and Tintest  between 
36.1 and 40.2 ºC during the three stages. Significant rises in mean serum CPK, hsCRP, sOsm and 
blood neutrophil count reached peak concentrations of 1 488U/L, 8.91mg/l, 298mosm/L and 
10.21 10^9/L (p≤0.001), respectively. No evidence of elevations in uMb and cTnT were detected.  
The stage-induced increments in DOMS correlated positively with CPK, r=0.71; 95% CI [0.62, 
0.78]. TC decreased significantly post S1post and S2post (p≤0.05) and a maximum mean body mass 
loss of 3.09% (±1.04%) occurred during S2.  There was no significant difference between non-
steroidal anti-inflammatory drug (NSAID) users and non-users in terms of serum CPK, hsCRP, 
cortisol, post race DOMS scores, running times, TC or sOsm (p>0.05).  The post-pre change in 
sOsm during each stage correlated inversely with the changes in % body mass, r = -0.36, 95% CI 
[-0.57,-0.094] and the pooled data examining the relationship between the change of sOsm and 
change in serum CPK for the three stages (n=57), revealed an insignificant positive correlation  
(r= 0.034, 95% CI [-0.228, 0.291].  
 
The maximum Tintest ranged between 38.3 º C and 40.2 º C and only exceeded 40º C in two of the 
12 athletes monitored.  The relationship between the change in Tintest and serum CPK was 
insignificant (p>0.05) for the 11 individuals from whom complete sets of data were available (r= 
0.24, 95% CI [-0.42, 0.734]. 
 
In the hypercholesterolaemic athlete, the maximum serum CPK (665U/L), hsCRP (1.9mg/Ll) and 
cortisol (845nmol/L) concentrations corresponded with undetected uMb despite a maximum body 
mass loss of 4.5% 
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Conclusion:   
Three consecutive days of 95km trail running resulted in low markers of muscle damage and 
inflammation, when compared to results obtained in previous single day road races of similar 
duration despite the maintenance of a  heart rate above 77% APmax, Tintest rising above 39o C and 
mean body mass decrement of  >2.0%.  The unchanged concentrations of serum cTnT and uMb 
confirmed the low values of the markers of muscle damage and inflammation.  An insignificant 
positive correlation between muscle damage and dehydration was noted.  
 
Furthermore the daily use of 0.4 mg/kg Atorvastatin in combination with 10mg Ezetrol did not 
result in the subject experiencing subjective myalgia, cramps, fatigue or increased markers of 
muscle damage following her participation in the trail run. 
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1.1   BACKGROUND TO THE STUDY 
  
Multiday ultra distance events are becoming increasingly popular among professional and 
amateur athletes and may encompass running, cycling and/or other disciplines.  Various studies 
have been published on the physiological changes that occur during single and multiday 
endurance road running and cycling events (Knechtle et al., 2008; Skenderi et al., 2006; 
Nieman et al., 2005), but few addressed the changes that occur during multiday endurance trail 
running races, which have been found to be different to single day ultra distance or marathon 
foot races (Millet et al., 2011).  
 
Running as an activity involves eccentric contraction of a large muscle mass including the hip 
and knee extensor muscles and muscles of the anterior and posterior tibial compartments 
during every stride (Eston et al., 1995).  This eccentric component is accentuated whilst 
running downhill when the muscle is forced to lengthen while contracting (Proske and Morgan, 
2001; Eston et al., 1995).   
 
Clarkson and Hubal (2002) attribute the muscle damage to an increased contractile load per 
unit, which occurs as fewer motor units are recruited.  This damage results in changes in the 
excitation-contraction (E-C) coupling, inflammation, swelling, decreased mobility and delayed 
onset muscle soreness (DOMS), which would increase in relation to the duration of the event 
(Clarkson and Hubal, 2002).  After eccentric exercise there is a presence of sarcoplasmic 
enzymes and proteins, including  creatine phosphokinase (CPK) in the serum and myoglobin in 
the urine, when there is leakage of these enzymes and proteins through the damaged 
membranes of muscle cells into the circulation (Martinez-Amat et al., 2005;  Clarkson and 
Hubal, 2002).  These findings are, however, not always reflective of structural muscle damage, 
as demonstrated by histological studies (Clarkson and Hubal, 2002;  Lieber and Friden, 2002) 




be reduced by other kinases, such as mitochondrial CPK and CPK-immunoglobulin complexes  
(Martinez-Amat et al., 2005).   In order to differentiate between skeletal and cardiac muscle 
damage, the concentration of cardiac troponin-T (cTnT) in the serum has been used as a 
reliable marker of cardiac, but not skeletal muscle damage (Martinez-Amat et al., 2005).   
 
Increased levels of markers of skeletal muscle damage in the urine including the presence of 
urinary myoglobin (uMb), have been shown to reflect asymptomatic exertional rhabdomyolysis 
that has been found to occur during prolonged endurance exercise (Knechtle et al., 2008; 
Skenderi et al., 2006; Clarkson and Hubal, 2002) and possibly be related to inflammation, 
DOMS and skeletal and cardiac muscle damage (Skenderi et al., 2006; Clarkson and Hubal, 
2002).  Knechtle et al.(2008) suggest that runners in a 1 200km multiday road running event 
experienced decreased skeletal muscle mass and increased total body water due to 
rhabdomyolysis and impaired renal function.    
 
The effect of muscle damage on inflammatory response is evident in the circulation as 
concentrations of neutrophils and the hepatic acute - phase protein, C-reactive protein (CRP) 
are raised (Robson-Ansley et al., 2009, Nieman et al., 2005).  Muscle damage during 
prolonged exercise is associated with an acute phase response, reflected by changes in pro-
inflammatory cytokine concentrations which, are in turn, correlated significantly with serum 
CRP (Robson-Ansley et al., 2009, Nieman et al., 2005).    
 
The use of non-steroidal anti-inflammatory drugs (NSAID) has been found to affect the 
inflammatory response, but not skeletal muscle damage during exercise (Nieman et al., 2005).  
It would therefore be interesting to compare the results of subgroups of athletes who used 
NSAID to non-users to investigate the relationship between the use of NSAID and markers of 
muscle damage and inflammation.  
 
Extensive research has also been conducted on the effects of exercise-induced dehydration and 
the physiological effects thereof (Casa et al., 2010; Stearns et al., 2009;  Cleary et al., 2006;  
Maresh et al., 2004; Cheuvront and Haymes, 2001).  Recent studies have found that the 




environment augments muscle damage (Cleary et al., 2005), but it is not known to what extent 
this would be affected by three consecutive days of trail running.  
  
The use of 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors or 
statins, the primary lipid-lowering medication currently prescribed for hypercholesterolaemia 
has been associated with muscle cramping, myalgia, fatigue and in rare cases, rhabdomyoloysis 
and death (Di Stasi et al., 2010;  Thompson et al., 2010;  Seachrist et al., 2005, Pasternak et 
al., 2002;  Evans and Rees, 2002).  It is, however, not known how the simultaneous intake of 
ezetemibe, a lipid uptake inhibitor, affects the augmented muscle damage, which has been 
found to occur when hypercholesterolaemic athletes on statin medication compete in endurance 
running events.  A case study of an athlete who uses these two medications concurrently, was 
therefore included to investigate her reaction to multiday ultra-distance racing. 
 
1.2   AIMS AND OBJECTIVES OF THE STUDY 
 
This observational cohort study firstly set out to determine the effect of a multiday trail running 
race over 95km on systemic markers of muscle damage and inflammation using blood 
neutrophil and serum CPK, hsCRP and cortisol concentrations, thigh circumference (TC), 
DOMS and uMb as markers of muscle damage and inflammation.   
 
Secondly, the effect of increased intestinal temperature (Tintest) and of dehydration, measured 
by serum osmolality (sOsm) and body mass changes, was also monitored to determine the 
relationship between Tintest, dehydration and muscle damage and inflammation. 
 
Thirdly, the effect of statin medication, at a dosage of 0.4mg/kg, combined with a lipid uptake 






1.3   HYPOTHESES 
 
During trail running the environmental demands, challenging terrain underfoot and steep 
ascends and descents are added stressors to contend with while running at least three hours per 
day (Millet et al., 2011).   It is hypothesized that, due to these added stressors, the eccentric 
component of skeletal muscle contraction during trail running will be exaggerated causing 
increases in systemic and urinary markers of muscle damage and inflammation, DOMS and 
TC, which will be augmented by dehydration and hyperthermia and reflected in a change in 
anthropometric values (Casa et al., 2010; Cleary et al., 2005, Sawka et al., 1998). 
 
It is furthermore hypothesized that the hypercholesterolaemic athlete included in the case study 
will experience muscle cramps and fatigue, which will be reflected in elevated systemic and 
urinary markers of muscle damage and augmented by dehydration. 
 
1.4   SCOPE OF THE STUDY 
 
This observational cohort field study was conducted during and after a three day trail run over 
95km. It was restricted to a convenience sample of twenty-one apparently healthy subjects of 
which nineteen (6 males, 13 females) completed all three stages of the race and 15 runners (4 
males, 11 females) completed all within and post- race assessments.   
  
Pre-race assessments included the recording of body mass and height, TC and four-site 
skinfold for the determination of % body fat. Self-reported data regarding the medical and 
training status, hydration and food intake and use of NSAIDS and chemical stimulants was 
obtained from questionnaires.   
 
During the race, urine and blood sampling were done before and after every stage and at 24 
and 72PR (post-race) and uMb, sOsm, cortisol, CPK, hsCRP, cTnT and blood neutrophil 
concentrations were determined. These results were correlated with sOsm and body mass 
changes as markers of dehydration, and Tintest, TC reflecting inflammation, were also measured 




the race as well as for the five days following the race to record subjective perceptions of post-









REVIEW OF THE RELATED LITERATURE 
  
EXERCISE INDUCED MUSCLE DAMAGE 
 
2.1 MECHANICAL DAMAGE 
 
Acute bouts of prolonged running, involving eccentric contractions, generate high levels of 
strain on the muscle because fewer motor units are recruited, putting more strain on those 
motor units (Friden and Lieber, 2001). Clarkson and Hubal (2002) propose that this results in a 
higher load per unit which eventually may lead to injury.  Lieber and Friden (2002) suggest 
that the initial damage to muscle is mechanical in nature, based on sarcomere strain.  The 
subsequent damage occurs due to inflammation and changes in the E-C coupling in the muscle 
(Clarkson and Hubal, 2002).  
 
With regard to mechanical damage, Proske and Morgan (2001) suggest that sarcomere 
disruption occurs at the sites of the weakest half-sarcomeres, which lengthen uncontrollably 
until the actin/myosin cross bridges are forcibly detached (Morgan, 1990) when the actin and 
myosin filaments slide past each other, according to the Huxley model (Huxley, 1974).  With 
repetition of the eccentric contraction, more of the next-weakest sarcomeres are strained and 
lengthened (Proske and Morgan, 2001).  These stretched sarcomeres are distributed randomly 
along the muscle fibre.  When the muscle relaxes, the overstretched sarcomeres may re-
integrate with the undamaged fibres and resume function (Lieber and Friden, 2002). However, 
with repeated eccentric contraction during exercise, weaker sarcomeres lengthen and become 
disrupted.  This leads to an extension in the optimum length of the muscle and at greater 
muscle lengths, membrane damage and tearing of the T-tubules occur, leading to inactivation 
of some sarcomeres (Proske and Morgan, 2001).  At this stage, before the necrosis of fibres, a 
fall in muscle tension would be reversible by the administration of caffeine which, in animal 




contraction of the muscle (Proske and Morgan, 2001).  The continued eccentric contraction 
leads to an increased number of disrupted sarcomeres, an increased local contraction and in 
return the passive tension in the muscle increases (Clarkson and Hubal, 2002).  With extensive 
damage and extensive local contraction, parts of, or the whole fibre dies and an irreversible 
secondary delayed fall in tension occurs about 24 hours after exercise which is not reversible 
with administration of caffeine due to the extensive damage that has occurred (Proske and 
Morgan, 2001).  Thereafter breakdown products of tissue necrosis cause a local inflammatory 
reaction, leading to oedema and soreness (Proske and Morgan, 2001).    
 
According to Huxley (1957), in his sliding filament theory of muscle contraction, the myosin 
filament head attaches to a single actin binding site, flexes and contraction of the fibre occurs 
in millions of sarcomeres in a single muscle.  The   Japanese scientist, Toshio Yanagida,  
proposed that the actin and myosin are involved in a series of loose couplings (Yanagida, 
2007) which explains eccentric contraction, but does however not explain the damage that 
takes place when the actin-myosin bond is forcibly detached, according to Huxley’s model.                                                                                                                                                                                                                                                                                   
                                                                        
 2.2   PRESENTATION  
 
Generally, there is a loss of strength of the affected muscle and a drop in active tension due to 
the mechanical damage and tissue necrosis (McHugh, 2003; Proske and Morgan, 2001), 
swelling, soreness and an increase in passive tension (or stiffness) leading to a reduced range 
of motion. Proske and Morgan (2001) postulate that stiffness occurs due to the local 
contraction and increased release of Ca2+ following the membrane damage.  Low frequency 
fatigue, the ability to generate force at a lower frequency, lasting up to a week post-exercise, 
has also been described (Clarkson and Hubal, 2002).   
 
DOMS, which has been reported to be unique to eccentric exercise, sets in several hours after 
eccentric exercise and peaks 24 – 72 hours later (Lambert and Dennis, 1994). Swelling and 
soreness appearing within 6 hours after exercise are ascribed to the local inflammatory 
response (Proske and Morgan, 2001) and to noxious chemicals such as histamines, bradykinins 




Group IV afferent sensory nociceptors and the muscle becomes tender to touch, stretch and 
contraction.   An accumulation of fluid in the muscle fibre causes increased pressure (Clarkson 
and Hubal, 2002) with swelling that may last up to 10 days post exercise. 
 
Some research questions whether inflammation is a cause or consequence of muscle damage.  
When comparing the time course of changes in the inflammatory response and the 
development of DOMS, Malm et al. (2004) found no correlation between these variables and 
concluded that DOMS is a result of muscle adaptation or of the activation of leukocytes that 
are present in the epimysium before exercise (Malm et al., 2004).  Other studies, using radio-
labeling of neutrophils, found that neutrophil infiltration into damaged muscle increased up to 
24 hours post-exercise, coinciding with DOMS and a secondary decrease in eccentric torque 
(Raastad et al., 2003).  
 
The elevated calcium levels also trigger the release of endogenous proteases such as calpain 
(Feasson et al., 2002;  Friden and Lieber, 2001), causing further muscle damage.  Calpain does 
not affect actin and myosin, but has an affinity for desmin and alpha-actinin (Feasson et al., 
2002; Friden and Lieber, 2001) contributing to the damage at the intermediate filament 
sections.  
 
The loss of the structural protein desmin, which links adjacent Z-disks (Bennett et al., 2005), 
has been noted in fibres that show signs of damage (Friden and Lieber, 2001). Desmin also 
helps to maintain proper alignment of sarcomeres within and between myofibrils (Boriek et al., 
2001) Immunostaining of animal tissue has shown that muscle fibres lose “staining”  for 
desmin within minutes after the initiation of eccentric contractions. In addition, the number of 
fibres that lack desmin increase with time following an eccentric exercise bout and those fibres 
that lose desmin staining demonstrate accumulation of plasma fibronectin, indicating a loss of 
membrane integrity in these fibres (Boriek et al., 2001).   
 
Dystrophin is a large cytoskeletal protein associated within the muscle sarcolemma and is 
thought to help maintain the integrity of the membrane during repeated mechanical loading that 




2001). Within six hours following eccentric exercise, dystrophin staining has been reported to 
be completely missing in some fibres, with accompanying loss of desmin and another 
structural protein, alpha-actinin (Hawke and Garry, 2001). To compound the loss of membrane 
stability, other members of the complex of proteins associated with dystrophin, specifically 
beta-spectrin and alpha-sarcoglycan, show signs of early damage following eccentric 
contractions (Blake et al., 2002). The number of affected fibres has been shown to increase for 
up to 2 days after exercise, indicating a progression of damage over time. It has been suggested 
that this rapid loss of membrane-stabilizing function may render the muscle fibres fragile and 
more susceptible to damage by further contractions (Hawke and Garry, 2001). 
 
 The loss of titin, a component in the A-band that plays an important part in the storage and use 
of elastic energy (Donovan, 2004) and links the myosin filament to the Z-disk, is a further 
possibility due to the overstretching of one half-sarcomere (Proske and Morgan, 2001) and the 
contraction of the other half.    
 
2.3  HISTOLOGICAL APPEARANCE OF DAMAGED MUSCLE CELLS  
 
The morphological findings indicate variable muscle fibre size (Grobler et al., 2004;  Friden 
and Lieber, 2001), hyper contraction of the fibres, loss of the A-band, distortion of the A-band 
and I-band alignment (Friden and Lieber, 2001), Z-disk streaming in mild damage and Z-disk 
smearing in severe cases, with dispersion of Z-disk materials into the adjacent sarcomeres 
(Clarkson and Hubal, 2002;  Friden and Lieber, 2001).  In the damaged areas focal loss of the 
Z-disk may occur as well as loss of lateral registration of myofilaments (Martinez-Amat et al., 
2005).  Enlarged mitochondria, sub-sarcolemmal mitochondria (Grobler et al., 2004) and lipid 
and glycogen accumulations are also present in the damaged areas.   
 
According to Lieber and Friden (2002) and Friden and Lieber, (2001), mainly type II fibres are 
affected because of their short fibre length and higher tension developed and their lack of 
oxidative capacity.  Proske and Morgan (2001), however, found that both fibre-types 
experience damage after eccentric exercise confirmed by a shift in the length-tension relation 




length-tension relation of the two fibre types was not statistically significant (Proske and 
Morgan, 2001). 
  
Activated satellite cells aid in muscle regeneration by proliferating and fusing to each other or 
existing damaged myofibres to form new fibres (Hawke and Garry, 2001), remodeling the 
damaged areas.  Factors affecting satellite cell activity include muscle fibre type, age and the 
secretion of multiple growth factors, a timeous immune response, neurotransmitters and 
neurotrophic factors (Hawke and Garry, 2001).  Without macrophage activity and their 
subsequent cytokine factor secretion, no muscle regeneration occurs (Hawke and Garry, 2001) 
 
2.4 SYSTEMIC MARKERS OF CELL DAMAGE IN SKELETAL AND CARDIAC 
MUSCLE 
 
Haematological findings after eccentric exercise include increased concentrations of the 
following muscle proteins in serum:  CPK, alpha-actin, myoglobin and troponin (Martinez-
Amat et al., 2005), CRP, lactate dehydrogenase (Lambert and Dennis, 1994) aspartate 
aminotransferase and carbonic anhydrase iso-enzyme II (Clarkson and Hubal, 2002).  The use 
of muscle proteins as indicators of muscle damage, however, reflect the difference between 
what is released from the tissue and cleared from the blood and can have large inter-subject 
variability in the response (Clarkson and Hubal, 2002).   
 
2.4.1 Creatine Phosphokinase (CPK):  Most researchers determine the extent of damage by 
using serum CPK concentration because of the low cost of the assay and because the increase 
in CPK concentration is high in comparison to that of other proteins (Clarkson and Hubal, 
2002).  It also is used clinically to diagnose myositis and rhabdomyolysis and to predict renal 
failure (Clarkson et al., 2006).  Exertional rhabdomyolysis may occur after strenuous exercise 
when serum CPK concentration is >500U/L and urine dipstick is positive for Mb and blood 
without haematuria (Knechtle et al., 2008;  Skenderi et al., 2006; Clarkson et al., 2006).  Renal 
failure has been associated with serum CPK concentrations > 20 000U/L, although Clarkson et 
al. (2006) found that marked CPK and Mb elevations alone, are not sufficient to result in renal 




environmental heat stress, sickle cell trait or drug use also contribute to this condition 
(Clarkson et al., 2006).  
 
CPK often shows a large standard deviation and it should be taken into consideration that it is 
affected by other kinases such mitochondrial CPK, CPK-immunoglobulin complexes and CPK 
derived from cardiac muscle (Martinez-Amat et al., 2005).  According to Knechtle and Kohler 
(2007), a significant decrease of skeletal muscle mass has been noted during a running race 
over 338km within five days, although the biggest change in muscle mass occurred after the 
first stage. 
2.4.2  Alpha(α)-actin:  A major constituent of the contractile apparatus in skeletal muscle is α-
actin which, when it leaks into the serum, has been found to be a reliable marker of muscle 
damage and to have a high diagnostic specificity especially within the first few hours after 
exercise (Martinez-Amat et al., 2005). The use of α-actin as a marker of skeletal muscle 
damage has a high sensitivity (63-100%), represent more than 20% of all muscle cell proteins, 
is detected within 1 hour after the onset of muscle damage and can be detected in the serum for 
up to 72 hours after its release, indicating greater stability over time (Martinez-Amat et al., 
2005).   
2.4.3 Lactate dehydrogenase (LDH):  LDH is a commonly used indicator of exercise induced 
muscle damage.  It reaches peak concentrations within six hours post exercise and returns to 
pre-exercise levels within 48 hours after exercise (Maughan et al., 1989).  However, elevations 
of serum LDH concentrations occur after any tissue damage, including cardiac muscle damage, 
hence the specific iso-enzyme must be measured.  Furthermore, large intra- and inter-
individual differences of serum LDH changes have been reported, reducing its specificity and 
sensitivity as a marker of exercise induced skeletal muscle damage (Martinez-Amat et al., 
2005).    
2.4.4 Plasma fatty acid binding protein (FABP):  FABP and myoglobin have been found to 
increase and decrease more rapidly than CPK inferring that it is possibly more useful than CPK 
for the early detection and monitoring of exercise-induced muscle damage (Sorichter et al., 




injury and the separate monitoring of skeletal muscle injury during repeated exercise bouts 
(Sorichter et al., 1998).  Pelsers et al. (2005), however, recommend that the clinical application 
of using FABP will require further commercialization of automated and rapid assays.  
2.4.5 Troponin: The effect of prolonged strenuous exercise on markers of cardiac muscle 
damage has been studied extensively.  Troponin markers are used as reliable markers of 
cardiac muscle damage and can be used to differentiate between cardiac and skeletal muscle 
damage (Martinez-Amat et al., 2005).   
 
The troponin subunits, cardiac troponin I (cTcI) and cTnT have been found to increase  
transiently during and immediately after exercise, returning to normal in healthy athletes within 
3 days (Frassl et al., 2008;  Middleton et al., 2008).  According to Leers et al. (2006) these 
increases could be due to myocardial stress, which is confirmed by Middleton et al. (2008) 
who state that the reversible cardiomyocyte membrane damage during exercise occurs due to 
an increased myocardial oxygen demand and cardiac troponin turnover in all athletes.   The 
cardiomyocyte damage might be linked to tachy-arrhythmias and sudden cardiac death, 
especially when associated with prolonged increased cTnT results above 0.05µg/l, the acute 
myocardial infarction cut-off (Middleton et al., 2008; Leers et al., 2006).    
 
2.5   INFLAMMATORY   RESPONSE 
 
Inflammation occurs in response to prolonged intense exercise (Clarkson and Hubal, 2002;  
Lieber and Friden, 2002;  Friden and Lieber, 2001;  Hawke and Garry, 2001) and is associated 
with the invasion of neutrophils and macrophages into the damaged fibres within 6 hours 
(Peake et al., 2005).  These leukocytes secrete reactive oxygen and nitrogen species, cytokine 
factors and proteolytic enzymes that cause an increase in satellite cell proliferation and 
differentiation (Friden and Lieber, 2001; Hawke and Garry, 2001) and tissue remodeling may 
occur (Clarkson and Hubal, 2002;  Feasson et al., 2002;  Friden and Lieber, 2001).   
 
2.5.1  Neutrophils, macrophages and cytokines:  Neutrophils remain present  in the damaged 




after exercise  and  produce pro-inflammatory cytokines including interleukin (IL)-1β and 
tumour necrosis factor (TNF)-α that initiate the breakdown of damaged muscle tissue (Peake et 
al., 2005).   
 
The systemic response to inflammation, on the other hand, rapidly becomes anti-inflammatory 
as plasma levels of IL-6, IL-10, IL-1ra and soluble TNF-α receptors rise in direct proportion to 
the intensity and duration of exercise (Nieman et al., 2005;  Peake et al., 2005).  The release of 
the pro-inflammatory cytokines into the circulation is inhibited by IL-6, which stimulates the 
production of the anti-inflammatory cytokines as well as the anti-inflammatory hormone, 
cortisol (Peters et al., 2001).      
 
In the160-km Western States Endurance Run event Nieman et al.  (2005) tested the 
relationship between plasma CPK, DOMS and various plasma cytokines.  These researchers 
found that muscle damage, post race DOMS and IL-6, IL-10, IL-1ra, granulocyte colony-
stimulating factor (G-CSF) and macrophage inflammatory protein 1β (MIP-1β) were positively 
correlated.  The increase in the cytokines was greatest for IL-6 (125-fold), corresponding with 
a 112-fold increase in CPK (Nieman et al., 2005). 
 
2.5.2  C-reactive protein (CRP):  Hepatocyte production of CRP during prolonged exercise is 
also activated by raised plasma IL-6 concentrations (Robson-Ansley, 2008) and a training 
induced reduction in serum CRP concentration has been confirmed following a prolonged 
period (Kohut and Senchina, 2004). However, only a small increase in CRP concentration is 
required to induce the release of IL-10 and IL-1ra by circulating monocytes and inhibits the 
synthesis of pro-inflammatory cytokines in tissue macrophages (Peters, 2004).  A strong 
correlation between serum CRP and IL-6 concentrations has been confirmed (Robson-Ansley, 
2008; Nieman et al., 2005; Peters et al., 2001). 
 
2.5.3 Cortisol: Cortisol is a glucocorticoid, secreted by the adrenal cortex and regulated by 
adrenocorticotrophic hormone (ACTH) from the anterior pituitary (Borer, 2003).  In response 
to dehydration, stress, increased core temperature and reduced glucose levels, corticotrophin-




(Borer, 2003).  It is essential to life, regulating carbohydrate, lipid and protein metabolism, 
assisting during stress and it has a minor effect on the kidneys during fluid regulation (Borer, 
2003).  Serum cortisol concentration is often elevated in times of physical or mental stress 
during which it increases the glucose available to the muscles by stimulating the breakdown of 
glycogen.  It also acts as a powerful anti-inflammatory hormone (Borer, 2003).  Cortisol 
secretion in the body normally follows a diurnal pattern, being highest between 5 – 10am and 
lowest between 8pm – 4am. In the case of athletes running a race, blood cortisol concentration 
may also be elevated in the morning due to anticipation, but do tend to increase further during 
prolonged exercise due to physiological stress (Borer, 2003).   
 
2.6   FACTORS AFFECTING MUSCLE DAMAGE AND INFLAMMATION 
 
2.6.1 Repeated Bouts:  After a single bout of unaccustomed eccentric exercise, a repeated 
bout (RB) of the same exercise results in reduced symptoms of muscle damage compared to 
the initial bout and has been referred to as the repeated bout effect (McHugh, 2003).  This 
effect is reported to last up to 6 months when there has been no intervening exercise between 
bouts (Clarkson and Hubal, 2002).  Even if the eccentric exercise is repeated within 2-6 days 
after the first bout, before the muscle was fully recovered, recovery is not delayed (Clarkson 
and Hubal, 2002).     
 
Various mechanisms have been postulated to explain the RB (McHugh, 2003), including 
inflammatory adaptation, which is confirmed by Peake et al. (2005) who found that there is a 
10 – 45% decrease in circulating neutrophil numbers after the repeated bout and a moderate 
attenuation in leukocyte receptor expression.  This corresponds with changes in serum 
myoglobin concentration and serum CPK activity (McHugh, 2003), which reflect a dramatic 
increase after the first bout, but only a small increase after the RB (Clarkson and Hubal, 2002).  
Peake et al. (2005) suggest that there is a decreased receptor expression after a RB which 
appears to be a secondary response to a reduced degree of muscle damage.   According to 
Clarkson and Hubal (2002), the increase in serum CPK concentration after a RB is less than 
expected.  They suggest that an increased clearance of CPK from the blood after the RB is 




 Other theories explaining the RB effect state that neural, mechanical or cellular adaptations 
occur (Radom-Aizik et al., 2009; Mahoney et al., 2008; Martinez-Amat et al., 2005; McHugh, 
2003).  According to McHugh (2003) the neural adaptation might be reflected by the increased 
recruitment patterns during the RB, although no difference was noted in the EMG/unit torque 
during the RB (Clarkson and Hubal, 2002).  McHugh (2003) attributes mechanical adaptations 
to increased desmin content during repair, causing increased dynamic and passive muscle 
stiffness with eccentric training.  On the cellular level, it is postulated that an increase in the 
sarcomere numbers in series and a decrease in the tendon length (Radom-Aizik et al., 2009; 
Clarkson and Hubal, 2002) within muscle fibres occur in response to the destruction of the 
weakest fibres during the initial bout.  These fibres are repaired, with an increase in sarcomere 
numbers in series and increased resistance to damage, which results in less damage during the 
RB (Clarkson and Hubal, 2002). 
 
The strength loss which occurs after exercise may be due to impaired E-C coupling according 
to McHugh (2003), who found that strength loss is similar immediately after the initial and RB 
of exercise but with less impairment after the RB on subsequent days.    
 
Proske and Morgan (2001) also report that the muscle spindles and tendon organs are damaged 
during severe eccentric exercise, increasing the resting activity of the muscle.  This rise in 
passive tension is a simple, non-invasive indicator of muscle damage and these researchers 
suggest that it can be used to determine the extent of damage instead of measuring the tension-
deficit, or the shift in the length-tension relationship.   
 
2.6.2  Dehydration, hyperthermia and muscle damage:  The hydration status of athletes  has 
been shown to detrimentally affect their pacing, physiologic function and thermoregulatory 
abilities (Casa et al., 2010;  Stearns et al., 2009;  Cleary et al., 2005). According to Casa et al. 
(2010), at a decrement of 2% body mass loss, increases in Tintest of 0.22oC and heart rate of 6 
beats per minute (bpm) were recorded for every additional 1% of body mass lost, which results 
in increased core body temperatures, heart rates, perception of effort and an altered anticipatory 




to lead to higher levels of muscle damage, heat stroke, rhabdomyolysis, renal impairment and 
even death (Casa et al., 2010; Knechtle et al., 2008).      
 
Casa et al. (2010) add that dehydrated athletes might have higher body core temperatures than 
euhydrated athletes, who can continue to perform at a higher intensity.  This is contrary to 
earlier findings (Cheuvront and Haymes, 2001;  Noakes et al., 1991 ) stating that the metabolic 
rate and not dehydration affects Tintest, although Cheuvront and Haymes (2001) added that 
metabolic rate, hydration status and environment all contribute to increased Tintest, but are 
influenced by individual differences in fluid intake and racing strategies.     
 
According to Cleary et al. (2005), skeletal muscle damage, as indirectly reflected by DOMS, 
was augmented in hyperthermic dehydrated athletes due to the elevated deep muscle 
temperature, which resulted in increased susceptibility of muscle fibres to damage and 
increased degradation and denaturation of structural and functional proteins.  However, 
dehydration alone did not augment DOMS (Cleary et al., 2005).  
 
When excessive skeletal mass loss, dehydration and haemolysis occur which could result in 
impaired renal function, rhabdomyolysis and myoglobinuria (Knechtle et al., 2008).  Clarkson 
et al. (2006), however found that despite exercise induced CPK and myoglobin elevations, 
renal impairment does not always occur.  Even when indicators of muscle and liver damage 
were extremely elevated after a 246km continuous running race, and exertional 
rhabdomyolysis occurred, the rhabdomyolysis was asymptomatic (Skenderi et al., 2006).   
 
2.6.3  Anti-inflammatory drugs: Friden and Lieber (2001) and Lieber and Friden (2002) 
investigated the administration of NSAID after eccentric exercise and reported a short term 
benefit of pain relief, but a long term detrimental effect on muscle adaptation, inhibiting 
protein synthesis by suppressing the inflammatory reaction.  This is contrary to Nieman et al. 
(2005), who found that NSAID users did not have reduced race times, muscle damage or 
DOMS, but had higher post race plasma levels of  IL-6, IL-8, G-SCF, MIP-1β and monocyte 
chemotactic protein 1. Paulsen et al. (2009), however, indicated that NSAID inhibited 




reducing intracellular cyclic adenosine monophosphate (cAMP), promoting chemoattractant 
binding and inhibiting changes in membrane fluidity.   
 
2.6.4 Lipid lowering medication: Three-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) 
reductase inhibitors or statins, are the primary lipid-lowering medication currently prescribed 
for hypercholesterolaemia, to reduce the amount of low-density lipoprotein (LDL) cholesterol 
(Thompson et al., 2010; Seachrist et al., 2005).   Statins specifically inhibit the rate-limiting 
enzyme HMG-CoA reductase in the liver, thus effectively reducing endogenous plasma 
cholesterol levels (Seachrist et al., 2005; Evans and Rees, 2002).  According to the latest U.S. 
Food And Drug Administration Safety Announcement (FDA Drug Safety Communication, 06-
08-2011), the FDA recommends limiting the use of the highest approved dose of simvastatin 
(80mg per day) (Seachrist et al., 2005;  Pasternak et al., 2002) due to the increased risk of 
muscle damage with muscle cramping, myalgia, fatigue and  in rare cases, rhabdomyoloysis 
and death (Di Stasi et al., 2010;  Thompson et al., 2010;  Seachrist et al., 2005, Pasternak et 
al., 2002;  Evans and Rees, 2002).   
 
Potential mechanisms to which side effects of statins in skeletal muscle have been attributed 
include: 
i. intracellular depletion of essential metabolites and destabilization of cell membranes, 
resulting in increased cytotoxicity, affecting the maintenance of skeletal muscle 
architecture (Di Stasi et al., 2010;  Seachrist et al., 2005),  
ii. the reduced production of isoprenoids such as ubiquinone, which participates in 
electron transport during oxidative phosphorylation in mitochondria (Di Stasi et al., 
2010;  Thompson et al., 2010),  
iii. impaired signal transduction and structural protein formation and regulation (Di Stasi et 
al., 2010;  Urso et al., 2005),  
iv. alterations in Ca2+ shuttling such that Ca2+ leaking from the mitochondria directly 
increases cytosolic Ca2+  and impairs sarcoplasmic reticulum calcium cycling 
(Thompson et al., 2010) and   
v. interactions with the cytochrome P-450 hepatic enzyme system (Evans and Rees, 




   
Atorvastatin and simvastatin are lipophilic statins which are absorbed via first-pass metabolism 
into gastro-intestinal and liver cells and which promote ease of diffusion through passive 
transport across the bilipid skeletal muscle cell membrane, causing augmented toxic effects on 
skeletal muscle at a dosage of >80mg.day (Di Stasi  et al., 2010;  Pasternak et al., 2002).  
During absorption, enzyme inhibitors such as calcium channel blockers, fibrates, anti-fungals 
and grapefruit juice can increase statin toxicity by competing with the statins (Di Stasi  et al., 
2010;  Seachrist et al., 2005; Evans and Rees, 2002;  Pasternak et al., 2002).  
 
At 0.5mg/kg-1 Seachrist et al. (2005) demonstrated changes to the morphology of mitochondria 
in skeletal muscle without concurrent CPK elevation or histological changes to the myofibre.  
These mitochondrial alterations occurred to a greater extent in Type II glycolytic fibres that 
have a lower content of mitochondria, than in Type I muscle fibres which are oxidative with a 
high content of mitochondria (Seachrist et al., 2005), which suggest the presence of an 
impaired oxidative metabolism. They concluded that toxicity occurred at ≥1mg/kg/day with 
significant increases in serum CPK, ALT, AST, plasma lactate concentrations and lactic 
acidosis and that this dosage might promote statin-induced muscle mass loss, cramping, 
fatigue, rhabdomyolysis and even death (Di Stasi  et al., 2010;  Seachrist et al., 2005; 
Pasternak et al., 2002).  Seachrist et al. (2005) reported that 78 % of professional athletes with 
familial hypercholesterolaemia could not tolerate statin therapy due to muscular problems. 
Predisposing risk factors include being female, the presence of renal or hepatic disease, 
advancing age and the use of concurrent medications (Di Stasi et al., 2010; Seachrist et al., 
2005; Pasternak et al., 2002).  There is also the possible implication of statins altering the 
response of muscle to exercise by affecting the action of the ubiquitin proteasome pathway, 
protein folding and catabolism, thus disrupting the balance between protein degradation and 
repair (Urso et al., 2005). 
 
It has been found (Riesen et al., 2002) that therapy with various statins decreases serum CRP 
concentrations even after 4 weeks of therapy, which shows a benefit for early statin treatment 
in acute coronary events and other chronic inflammatory conditions (Thompson et al., 2010;  




despite the reported lack of clinical data concerning the direct effects of statins on skeletal 
muscle function (Thompson et al., 2010).      
 
The use of another drug, Ezetimibe (Ezetrol), a lipid uptake inhibitor, has also been associated 
with muscle cramping, myalgia, fatigue and  in rare cases, rhabdomyoloysis and death (Di 
Stasi et al. 2010;  Thompson et al., 2010;  Seachrist et al.,2005, Ballantyne et al., 2003;  
Pasternak et al., 2002;  Evans and Rees, 2002).  Ezetimibe selectively inhibits the intestinal 
absorption of dietary and biliary cholesterol into the serum, reducing the delivery of intestinal 
cholesterol to the liver. It also attenuates the hepatic cholesterol stores and increases 
cholesterol clearance from the blood (Ballantyne et al., 2003).  The co-administration of 
Ezetimibe and Atorvastatin has been found to reduce LDL-cholesterol and CRP more than 
Atorvastatin alone (Ballantyne et al., 2003).  Although Ezetimibe is well tolerated, related 
adverse events include diarrhea, elevated skeletal muscle damage and hepatic dysfunction 
(Ballantyne et al., 2003).  Co-administration with Atorvastatin might increase the risk of 
myopathy and rhabdomyolysis (Ballantyne et al., 2003).    
 
2.6.5 Genetics:  Genetic predisposition might be the most interesting determinant of muscle 
damage, recovery and performance.  Being a relatively new field of study, already it has found 
that some individuals, those with single nucleotide polymorphisms in the IGF-II gene 
(Devaney et al., 2007), are more susceptible to muscle damage and thus less likely to excel or 
participate in sport.  Genetics also determine the cardiovascular, explosive power and 
maximum oxygen uptake abilities of an individual (Radom-Aizik et al., 2009;  Seene et al., 
2009;  Mahoney et al., 2008;  Virtanen and Takahashi, 2008;  Coffey and Hawley, 2007).  
Furthermore, several changes in gene expression occur after exercise (Radom-Aizik et al., 
2009;  Seene et al., 2009;  Mahoney et al., 2008;  Virtanen and Takahashi, 2008;  Coffey and 
Hawley, 2007) and analyzing these changes may be revolutionary to exercise physiology with 
regard to selecting training programs, means of recovery or the most appropriate sport for each 
individual (Virtanen and Takahashi, 2008).  There are genes that determine endurance and 
strength (angiotensin-converting enzyme gene, actinin 3, growth hormone/IGF regulators); 




carrying capacity in the blood and many more (Radom-Aizik et al., 2009;  Mahoney et al., 
2008;  Goldspink, 2003).    
 
2.6.6 Chromosome telomere erosion: Chromosome telomere erosion might contribute to 
muscle and immune dysfunction, morbidity and mortality (Simpson and Guy, 2009).  
Telomeres are deoxyribonucleic acid (DNA) nucleo-protein complexes that cap the ends of 
chromosomes, promoting their stability.  These telomeres shorten progressively with each 
round of cell division and are not fully replicated unless counteracted by elongation by 
telomerase, thus affecting muscle function (Puterman et al., 2010).  Excessive telomere erosion 
presumably occurs due to repeated exposure to pathogens and/or oxidative stress (Simpson and 
Guy, 2009).   
 
2.6.7 Oxidative stress:  Part of the response in muscle during eccentric exercise is the increase 
of free radical activity (Grobler et al., 2004; Feasson et al., 2002;  McArdle et al., 2002) that 
might initiate the adaptive response in muscle, stimulating the production of anti-oxidant 
enzymes and various proteins, including the important heat shock proteins. After stress the 
amount of intracellular heat shock proteins (HSP) increase (McArdle et al., 2002; Hawke and 
Gary, 2001) where they are associated with repair and homoeostasis by ensuring the correct 
folding and functioning of new proteins.  The increased number of HSP also provides 
protection against more damage (McArdle et al., 2002).  The use of anti-oxidant supplements 
like Vitamin C (Jackson et al., 1999) and tart cherry juice (Connolly et al., 2007) has been 
found to improve this reaction.   
 
The production of anti-oxidant enzymes such as superoxide dismutase and catalase is enhanced 
by regular endurance exercise (Peters et al., 2009; Radak et al., 2005; Bruunsgaard and 
Pedersen, 2000). Reactive oxygen species (ROS) have effector functions in cellular 
metabolism, signaling and host defense (Bruunsgaard and Pedersen, 2000).  A decreased 
generation may cause signaling deviations and increased concentrations might cause ROS-
mediated damage to cellular components, thus contributing to immune system dysfunction, 
chronic inflammation and autoimmunity (Peters et al., 2009).  In contrast to this, moderate 




endocrine hormones, which might reduce the accumulation of autoreactive immune cells and 
increase cell death (Bruunsgaard and Pedersen, 2000).  
 
According to the hormesis-theory, low concentrations of ROS may have a stimulating, 
beneficial effect. McArdle et al. (2001) found that a single bout of intense exercise causes an 
increased production of ROS which leads to oxidative damage to lipids, DNA and proteins.  
Regular moderate exercise, however, might stimulate tolerable transient increased ROS 
production, might change signaling pathways or cause mild molecular damage and thus induce 
adaptive responses that protect against subsequent stressors (Radak et al., 2004).  To support 
this theory, Radak et al. (2004) quote studies that demonstrated that exercise upregulates the 
antioxidant system and stimulates the oxidative repair system possibly by increasing the 
activity of the proteasome complex.  The proteasome complex is involved in the reduction of 
oxidatively modified proteins, resulting in a faster turnover of proteins and a reduced post 
translational period, thus providing a mechanism for damaged proteins to be replaced by intact, 
efficient proteins (Radak et al., 2004).   
 
2.6.8 Age: Various studies have shown that exercise reduces the chronic low grade systemic 
inflammation that occurs after 35 years of age and that it attenuates the effects of sarcopenia 
(Simpson and Guy, 2009; Peake et al., 2005).  The elderly with increased muscle mass were 
reported to have an increased number of NK cells, thus an improved resistance against various 
infections, and an improved efficacy to vaccination, further improving resistance to infectious 
diseases (Simpson and Guy, 2009; Krause, 2003).  According to Peake et al. (2005) ageing 
generally impairs the leukocyte mobilization and migration into skeletal muscle which impairs 
tissue remodeling.  Long term moderate exercise stimulates the secretion of various anti-
inflammatory cytokines, such as IL-6, which inhibits the secretion of pro-inflammatory 
cytokines and delays the decrease in neutrophil numbers (Peake et al., 2005; Krause, 2003) 
    
2.6.9 Gender: According to Peake et al. (2005) there are no general differences in the muscle 
damage after exercise between males and females.  It has, however, been reported that males 
display higher levels of serum CPK due to their larger muscle mass, although it was found that 




after unaccustomed exercise (Clarkson and Hubal, 2002).  Ronkainen et al. (2009) suggest that 
oestrogen offers protection to muscle damage, although further studies are recommended, 
examining the difference in male and female membrane permeability which could be reflected 
by the increased oedema that was noted in the muscle fibres of men after resistance training 
(Roth et al., 2000).  Regarding the inflammatory response, Peake et al. (2005) mention that 
females show increased concentrations of neutrophil infiltration 24 hours after eccentric 
exercise and oestrogen augmented macrophage infiltration after the RB. 
  
2.6.10 Other: Various methods have been examined to prevent or treat DOMS, with 
inconclusive results.  Stretching before and after eccentric exercise seems to have no effect 
(Herbert and de Noronha, 2007) neither did ice water immersion (Sellwood et al., 2007), nor 
hyperbaric oxygen therapy (Boriek et al., 2001).  Vibratory massage and massage have been 
reported to have some positive effects (Zainuddin et al., 2005;  Pietzsch, 2004) although timing 
of the massage therapy after  eccentric exercise appears to be crucial and should occur during 
the inflammatory stage (Zainuddin et al., 2005;  Pietzsch, 2004). Many athletes use ice water 
immersion, compression garments and hyperbaric therapy and it has been found that whole 
body cryotherapy (three minutes at -110oC) immediately after exercise enhanced muscular 
recovery by restricting the inflammatory process (Pournot et al., 2011).  The use of the omega-
3 polyunsaturated fatty acids, docosahexaenoic and eicosapenetaenoic acid have been found to 
induce anti-inflammatory effects through altering the cyclooxygenase 2 and lipoxygenase 5 
pathways by suppressing the production of prostaglandins and leukotrienes that modulate the 
production of pro-inflammatory cytokines (Tartibian et al., 2009). 
 
The protective effect of oestrogen on muscle damage has been supported in the study by Roth 
et al. (2000), proving that older females experience more muscle damage than younger females 
after eccentric exercise.  Ronkainen et al. (2009) showed that females on hormone replacement 





2.7  CONCLUSION 
 
Despite a substantial amount of published research providing evidence of histologic changes 
and systemic markers of skeletal muscle damage and inflammation following single stage 
road- and trail running events, and the factors which affect this, little, if any evidence, is 
available on skeletal muscle damage following multi-day trail running. Although Knechtle et 
al. (2008) found that the eccentric component of multi-day road running lead to the 
accumulation of total body water and the loss of skeletal muscle mass due to skeletal muscle 
damage, which caused rhabdomyolysis and impaired renal functioning, the accumulative effect 
of multiday trail running has not been investigated.  This exposes a gap in the literature, which 
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Objectives: To investigate the effect of a three-day trail run on markers of muscle damage 
 and inflammation in recreational runners. 
 
Method:  An observational cohort study was conducted on 19 recreational male (n=6)  and 
female (n=13)  athletes during a 95km trail run consisting of three stages, covering 29.3, 37.9 
and  27.8 km with peak elevation gains and losses of 1226 and 1231m,  respectively. 
 
Main Outcome Measures:    Pre-and post-stage and 24 and 72 h post-race concentrations of  
serum creatine phosphokinase (CPK), high sensitivity C-reactive Protein (hsCRP), cortisol, 
cardiac Troponin T (cTnT), and osmolality (sOsm) as well as urinary myoglobin (uMb), 
changes in body mass, delayed onset muscle soreness (DOMS) and thigh circumference (TC) 
were measured. Continuous recordings of heart rate (HR) and intestinal temperature (Tintest ) 
were made  throughout each stage. 
 
Results:  Heart rate ranged between 77 and 83% age-predicted-maximum (APmax) and Tintest 
between 36.1 and 40.2 ºC during the three stages. Significant rises in mean serum CPK, 
hsCRP, sOsm and blood neutrophil count reached peak concentrations of 1488U/L, 8.91mg/l, 
298mosm/L and 10.21 10^9/L (p≤0.001), respectively. No evidence of elevations in uMb and 
cTnT were detected.  The stage-induced increments in DOMS correlated positively with CPK, 
r=0.71; 95% CI [0.62, 0.78], TC decreased significantly post S1post and S2post (p≤0.05) and a 
maximum mean body mass loss of 3.09% (±1.04%) occurred during S2.    
Conclusion:  Three consecutive days of 95km trail running resulted in modest increases in 
markers of muscle damage and inflammation, despite the maintenance of a  heart rate above 





Trail running events are becoming increasingly popular with amateur athletes.1  These are 
generally regarded as more strenuous than road running due to the nature of the  trails, which 
can involve diverse challenges including single track paths on steep ascends and descends in 
mountains, crossing rivers and running along grasslands and through forests.2   Although 
physiological response to single-day trail running has been assessed,1-4 the accumulative effects 
of multi-day trail running on markers of muscle damage and inflammation have not yet been 
reported to date. 
 
Prolonged endurance exercise causes muscle damage that initiates an inflammatory response 
and subsequent remodeling of muscle.5 The extent of this damage is augmented by increases in 
exercise intensity, the eccentric component of contraction6-8 heat stress index and dehydration.3   
The greater contractile load per unit in muscles of the lower limb, as they contract eccentrically 
during downhill running,8  has been associated with increased mechanical damage to the 
muscle fibres, resulting in muscle membrane leakage and elevated concentrations of circulating 
muscle enzymes and proteins.9 Systemic markers of inflammation also rise5,7 and swelling, 
decreased mobility and delayed onset muscle soreness (DOMS) are common.5,6  The presence 
of  myoglobin in the urine has been reported in severe cases.5 
 
Although the direct cause and effect relationship between dehydration and hyperthermia is 
currently contentious10,  it has been reported that these augment exercise-induced muscle 
damage,3,4  detrimentally affect performance and pacing during trail running and increase post-
exercise DOMS.3,4,11  Cleary et al.11 reported an association between dehydration and 
hyperthermia and attributed an increase in muscle damage to the increased degradation of 
muscle proteins with elevated deep muscle temperature.  
 
The aims of the study were therefore to determine effects of a multiday trail run on the markers 
of muscle damage and inflammation in experienced recreational runners, measuring serum and 
urinary levels of selected skeletal muscle, cardiac and hepatic proteins in association with 
changes in red and white blood cell and serum cortisol concentrations before and after every 




assess the possible effect of dehydration and hyperthermia on the markers of muscle damage 
and inflammation.  
  
It was hypothesised that the three consecutive days of trail running would result in elevations 
of systemic and urinary markers of skeletal muscle damage and inflammation that are higher 
than previously reported during road running events of similar duration, and that the muscle 





This eight-day observational cohort study took place during a 3-day trail run and for 5 days 
following completion of the Three Cranes Trail Run, at Karkloof, KwaZulu-Natal, South 
Africa on 25 – 27 Feb 2011.   
  
Following approval by the relevant institutional research ethics committee (Ref No: BF 
210/010), subjects gave written consent after having been informed of the experimental 
procedures.     
  
Subjects 
Twenty-one apparently healthy recreational athletes, who met the inclusion criteria (age: ≤ 50 
and an average training distance of 60km per week) and did not use chemical stimulants, were 
accepted into the study. Nineteen (6 males, 13 females) completed all three stages of the race 
and 15 runners (4 males, 11 females) completed all within and post- race assessments.  Twelve 
athletes used NSAID’s during the race. 
 
Setting 
The Three Cranes Trail run, over 3 days and a total distance of 95km, was divided into 3 
consecutive stages comprising 29.3, 37.9 and 27.8 km, starting and finishing each day at the 




Figure 1: The topographical features of the three stages and selected images of the running 
terrain 
    
           
         





provided for the duration of the race, including at the aid stations along the route.  The routes 
consisted of gravel and forestry roads, narrow rocky mountain footpaths and grassy jeeptrack. 
Elevation gains reached 1020, 1226 and 680m, while elevation losses were recorded at 1021, 
1231 and 687m during S1 (Stage 1), S2 (Stage 2)  and S3 (Stage 3)  respectively (Table 1).  
The topographical features of the three stages, as well as selected images of the running terrain, 
are presented in Figure 1.  
 
Table 1:  Elevation changes (m) and ambient temperature ranges during the three stages of the 
trail run 





range (º C) 
Day 1 1020 1021 11.5 - 21.7 
Day 2 1226 1231 12.4 - 22.8 
Day 3 680 678 12.1 - 21.2 
Total 2926 2930  
 
Baseline measurements 
Following race registration the afternoon before the race, basic anthropometric measurements 
were recorded, including body mass (kg), stature (cm) in bathing suits without shoes, thigh 
circumference (TC) (measured 15 cm above the superior border of the patella) and four-site 
skinfold (suprailiac, subscapular, biceps  and triceps) for the determination of % body fat.12  A 
pre-race questionnaire detailing the athletes’ running and racing experience, training terrain 
and health status was also completed. 
 
Daily protocol  
Pre stage: The subjects presented themselves to a designated testing area 30-90 minutes before 
the start of the stage, handing in a first early morning urine sample. TC was measured, venous 
blood sampling was conducted in the seated position and resting heart rate (HR) and blood 
pressure (BP) were recorded after a 3-5 minute period of relaxation.  A simple pre-stage 
questionnaire including rating of the degree of muscle soreness they were experiencing was 




during the stage. After breakfast and final voiding of bladders, body mass (measured in 
running attire without shoes), was taken within 5 minutes prior to the start of the event. 
 
Within-stage: Environmental conditions and temperature were supplied on the hour by a 
meteorological station located 9.5 km from the base camp.  Heart rate was recorded using a 
polar HR monitor (Polar Electro OY, Finland) at five-minute intervals and % age predicted 
max (APmax) was determined according to the formula, 220-age.14   
A subsample of 12 athletes volunteered to ingest the Cor-Temp disposable tablets, containing 
temperature sensors (HQ Inc, Palmetto, FL), at least three hours prior to the start of each stage.  
The HR and intestinal temperature (Tintest) data are part of a more detailed study focussing on 
the relationship between Tintest, HR and hydration status.13   
Post stage: The subjects proceeded directly to the designated testing area where BP, mass and 
TC were measured within 3-5 minutes, blood and urine samples were taken and a short DOMS 
and post-stage questionnaire, providing details regarding the use of non-steroidal anti-
inflammatory drugs (NSAIDs) and muscle soreness, were completed.  In available athletes 
(n=10), a further measurement of TC was taken four hours after completion of S1 and S2.  
 
The same protocol was followed pre- and post stage on the three days of the race.   
 
Post-race:  At 24PR and 72PR, participants presented for further blood/urine sampling, BP, 
HR and anthropometric measurements. They were also requested to complete a DOMS 
questionnaire for the five days following the race, using a five-point Likert scale and return this 
together with a general post-race questionnaire, following completion of the study.   
  
Haematological analysis and anthropometric measurements 
All measurements were carried out by the same researcher for all subjects and on all occasions.  
Venous blood samples were drawn from the antecubital fossa, with subjects in the seated 
position, within 5 - 15 min of completing the stage.  Blood samples for the assessment of full 
blood count (FBC) and serum osmolality (sOsm) and urine samples were stored at 4ºC and 




an Advia-120 Hematology Analyzer (Siemens Healthcare Diagnostics, Deerfield, IL) and 
included erythrocyte indices and differential leukocyte counts. Plasma volume (PV) changes 
were determined from pre- and post-exercise haematocrit and haemoglobin concentrations 
according to the method of Dill and Costill.15 All concentration dependant, post stage blood 
cell parameters (leukocyte counts, cortisol, CPK and hsCRP values) were then adjusted for 
percentage change in PV. Both urine and serum osmolality were measured by freezing point 
depression, using a Kyoto Daiichi osmostat, OM 6020 (Japan).  Urine samples were also 
assessed for myoglobin (uMb) and specific gravity using the refractive index method on a 
Beyer Test Strip.   
 
Further aliquots of serum, separated by centrifugation @ 3000rpm and stored in dry ice were 
transferred to an -80 º ultrafreezer or transported to a commercial Pathology Laboratory for 
analysis of creatine phosphokinase (CPK), cortisol, cardiac troponin T (cTnT) and high 
sensitivity C-reactive protein (hsCRP) concentrations.  
 
Statistical analyses 
Data are presented as mean ± standard deviation (SD). The significance of the accumulative 
time-dependent stage-induced changes from pre-race (S1pre) to post race (S1post, S2post, S3post), 
as well as recovery rates were assessed comparing S2pre, S3pre, 24PR and 72PR to baseline 
(S1pre,), S2pre and S3pre were  assessed for the entire group using repeated measures one way 
analysis of variance. The time point of the significant differences was confirmed using a Tukey 
post hoc analysis.   
 
Comparisons between NSAID users and non-users were conducted using independent 
student’s t tests. Pearson’s product moment co-efficient of correlation, with a confidence 
interval (CI) of 95%, was used to test the relationship between the changes in measured 
outcomes including CPK, neutrophil concentrations, hsCRP and serum cortisol.    
  
All statistical calculations were performed using SPSS, version 18 (SPSS Inc., Chicago, USA). 








Temperature recorded on the hour during the three stages of the race ranged from 11.5º C to 
22.8 º C (Table 1). It did not rain, maximum windspeed recorded was 2.8 m/s and the relative 
humidity ranged from 54- 97%.  
 
Subjects  
As is shown in Tables 2 and 3, athletes ranged from 25 to 50 years of age, their weekly training 
distance averaged 65.9 ±20.1km per week for 12.4 years (range 2 – 27 years) and they 
presented without abnormalities in their vital signs.  Of the 19 subjects, 12 used NSAIDs, 
including aspirin, ibuprofen and diclofenac.   
 
Table 2. Mean ± SD baseline physical characteristics of subjects (n =19) 
Variable Mean ±SD 
Age (years) 39.3 ±7 
Height (cm) 169.0 ±10 
Mass ( kg) 65.8 ±12 
% body fat  21.7 ±4 
Resting heart rate (bpm) 56.9 ±5 
Systolic Blood Pressure (mmHg) 124.7 ±7 
Diastolic Blood Pressure(mmHg)  81.8 ±7 
 
Of the 21 subjects who initially agreed to participate in the study, one subject (male) withdrew 
after S1 due to an ankle injury and another (female) after S2 due to medical reasons. The 
baseline physical characteristics of the remaining 19 subjects are provided in Table 2.  Four 







Table 3  Training status and performance characteristics of athletes (n=19).             
 Characteristics Mean ± SD Range 
Running experience 
  Number of years 





 2 – 27 
18 – 500 
Weekly Training Distance   




12.5 – 105 
Number of days per week on different training 
terrains 
     Hills 
     Off Road incl. forest /trail/beach      











Race Time  
(hour:minute:second) 
  Stage 1                                                              
  Stage 2 








3:06:06 – 5:22:48 
4:14:56 – 7:46:27 
2:38:38 – 6:51:50 
Mean as %APmax* 
  Stage 1 
  Stage 2 









Data presented as mean (± SD) and range; *age-predicted maximum (220-age) 
 
Intensity of Effort 
The mean ±SD and range, of time spent completing each stage and average HR on the run, are 
given in Table 3. Total average running time of the athletes was 12h57±2h51.   
Markers of muscle damage and inflammation 
As shown in Table 4, these included a significant increase in circulating neutrophil 
concentrations (p≤0.001) which peaked at 10.21±1.54 10^9/L at S1post, serum CPK and hsCRP 
which peaked at S3post at 1488±1053U/L (p≤0.001) and 8.91±6.63mg/L (p≤0.001), 




An exercise-induced increase in serum cortisol concentration was only detected following 
S2post. TC decreased significantly from 54.1±4.4cm at S1pre to 51.8±3.9cm at S1post (p≤0.001) 
and returned to the pre-race measurement of 54.1 ±4.0cm at 24PR. DOMS ranged from 
4.8±1.6, 5.6±1.8 and 5.1±1.1 at S1post, S2post and S3post, respectively, and decreased to 1.73 ±1.3 
at 24PR.  
 
Significant positive correlations were evident between blood neutrophil concentrations and 
serum CPK, r = 0.27, 95% CI [0.11, 0.41], serum CPK and hsCRP concentrations, r=0.50, 95% 
CI [0.29, 0.66] and DOMS and CPK, r=0.71, 95% CI [0.62, 0.78]. 
 
Dehydration, intestinal temperature (Tintest), HR and muscle damage 
The mean % body mass loss for the entire group (n=19) during the three stages was 2.9±0.7, 
3.1±0.8 and 1.9 ±0.9, while the mean sOsm (n=19) increased from  288.9±4.8 to 293.7±5.7 
(p=0.003), 288.4±6.4 to 295.6±6.0 (p=0.003) and 292.2±4.1.to 295.0±5.6 (p=0.006) mOsm/kg, 
during S1, S2 and S3, respectively. When the pooled data for each stage were compared 
(n=51),  the paired  post-pre changes in sOsm correlated inversely with the changes in % body 
mass, r = -0.36, 95% CI [-0.57,-0.094].     
 
The pooled data examining the relationship between the change of sOsm and change in serum 
CPK for the three stages (n=57), revealed an insignificant positive correlation  (r= 0.034, 95% 
CI [-0.228, 0.291].  
 
The maximum Tintest ranged between 38.3 º C and 40.2 º C and only exceeded 40º C in two of 
the 12 athletes monitored (Table 5).  The relationship between change in Tintest and serum CPK 
was insignificant (p>0.05) for the 11 individuals from whom complete sets of data were 





Table 4:  Mean±SD white and red blood cell indices and markers of muscle damage and 
inflammatory response before and after every stage and at 24PR and 72PR. 
Variable  Stage 1 Stage 2 Stage 3 24PR 72PR 
 Pre Post Pre Post Pre Post 




























































































































hsCRP (mg/L) 0.7 
±0.5 



















uMb (mcg/mL) n/d n/d n/d n/d n/d n/d n/d n/d 



















*vs. S1pre, p≤0.001; ** vs. S2 pre, p≤0.001; ***vs S3 pre, p≤0.001    




Table 5:  Individual Tintest , and associated HR, changes in hydration status and peak serum 






























1 39.2 36.6 38.5 176 167 100 95 -3 -3.4 # 
2 38.7 37.2 38.3 161 148 94 87 -6 -2.9 772 
3 39.4 37.3 38.7 164 153 88 82 13 -2.7 1562 
4 39.6 36.8 38.7 193 144 112 83 -6 -4.1 1057 
5 39.2 35.2 37.4 168 154 95 87 10 -2.8 1523 
6 39.8 36.1 37.7 168 160 92 87 7 -3.1 4478 
7 38.7 36.9 38.2 152 140 89 82 11 -3.0 772 
8 39.2 37.3 38.1 180 159 95 72 -23 -2.3 1198 
9 40.2 37.1 38.0 181 144 102 81 -5 -3.3 1076 
10 38.9 37.4 38.4 156 150 84 81 5 -3.2 1089 
11 38.3 35.8 37.4 146 135 84 78 6 -2.8 1057 
12 40.1 37.3 38.5 171 149 90 79 7 -2.3 1151 
Mean  39.3 36.8 38.2 168 150.3 93.8 82.8 4.17 2.99 1430 
SD 0.6 0.7 0.4 13.4 9.0 8.0 5.8 9.42 0.49 1042 
Tintest: intestinal temperature; Max: maximum;  Min: minimum; HR:  heart rate;  bpm:  beats 
per minute; SD: standard deviation; *age-predicted maximum heart rate14; CPK: creatine 
phosphokinase;  #subject withdrew after completing S1   
 
Users of NSAIDs 
The 12 athletes who used NSAIDs had maximum serum CPK and hsCRP concentrations of 
1332±943.5U/L and 8.58±6.7mg/L at S3post and the non-users 1754±1251.3U/L and 
9.47±7.0mg/L, with no significant difference between the groups (p=0.456; 0.788).  The 
neutrophil count reached a maximum of 9.95± 2.1 and 9.75±0.4 10^9/L, respectively, for users 
and non-users (p=0.82).  There was also no significant difference between NSAID users and 








Evidence of muscle damage and inflammation  
The results of the present study indicate that very little muscle damage and inflammation 
occurred during three days of trail running despite athletes running for a total average of 12h57 
at an average HR of 77 – 83% APmax (Table 3).  The serum CPK concentration which 
increased progressively to reach peak concentrations at S3post, indicated only a mild 
accumulative effect of muscle damage during the race, which rejects the original hypothesis. 
Furthermore, the changes in neutrophil count, serum cortisol and hsCRP concentrations and 
DOMS also confirm low levels of inflammation and a rapid recovery. Most athletes in our 
study had no muscle soreness at 72PR, which correlated with the CPK concentration that had 
dropped close to the clinical upper limit of normal16 by 72PR. The consistently low release of 
muscle proteins into the bloodstream in all 19 subjects, which was also not accompanied by 
elevation in cTnT and uMb in this study, confirms a profile of low degrees of muscle damage.  
Further evidence is the fact that TC was not significantly elevated at any post-stage or post-
race time-point, but was reduced after S1 (p≤0.001), confirming previous findings of reduced 
swelling and a post-race decrease in muscle mass.17 
 
The low systemic markers of muscle damage and inflammation, when compared to previous 
findings following the Comrades Marathon17 confirm the findings of Millet et al.1 who, in their 
study on the neuromuscular consequences of extreme running in a 166km mountain ultra-
marathon, reported that post race serum concentrations of CPK, hsCRP and neutrophils were 
lower than those measured after a road race with similar finishing times.1 These researchers 
attributed their findings of low concentrations of systemic markers of  muscle damage and 
inflammation to the relatively soft underfoot surfaces and to the athletes frequently being 
forced to walk, jump, and climb due to the technical demands of the terrain.  
 
During extensive exercise-induced muscle damage myoglobin may be released into the urine 
and be indicative of exertional rhabdomyolysis and possible risk of renal failure.8   Clarkson,9 




CPK elevations without renal impairment. In our study the absence of uMb was confirmed by 
the relatively low increases in systemic neutrophil, serum CPK and hsCRP concentrations.   
 
In this study, we suspect that although the primary factor which reduced the amount of 
repetitive and eccentric unidirectional stress encountered during the race, was most probably 
the underfoot surfaces the majority of which were primarily soft, large fluctuations in the pace 
of running and varied muscle recruitment patterns over the different terrains, may also have 
played a role.  
 
The positive correlation found between DOMS scores and CPK concentrations supports  the 
findings of Nieman et al.2 who, in their study on 60 participants in the 160 km one-day 
Western States Endurance Trail Run in the Sierra Nevada Mountains in northern California, 
showed that there were significant associations between CPK, muscle soreness and the 
cytokines, interleukin (IL)-6, IL-10, IL-1ra (receptor antagonist), granulocyte colony-
stimulating factor and macrophage inflammatory protein 1β.      
 
Systemic markers of cardiac damage   
The effect of prolonged strenuous exercise on systemic cardiac markers of damage has been 
studied extensively19-21  with evidence of transient elevations during and immediately after 
exercise, which return to normal within 3 days in healthy athletes.19,20 These temporary 
elevations have been hypothesised to be due to myocardial stress and reversible cardiomyocyte 
membrane damage.19, 20  Exercise  is known to cause an increased myocardial oxygen demand 
and cardiac troponin turnover in all athletes,19 which might be linked to tachyarrhythmias and 
sudden cardiac death, when associated with prolonged increases (> 3 days) in cTnT 
concentrations above 0.05µg/l.19 At no stage during our study were increased cTnT 
concentrations however measured.  This supports the attenuated increase in serum CPK 
concentration and absent uMb values as well as the lower concentration of serum cortisol 
despite maintenance of an intensity of effort which fluctuated from 63 – 112% APmax. It is 
possible that serum cTnT also did not increase due to the variation in HR (60 – 220bpm) that 
occurred during this race, which may have stimulated the cardiac muscle at irregular intervals 





Users of NSAIDs 
Both NSAID users and non-users were included in this study following recent findings that 
although markers of muscle inflammation are changed by NSAID usage, degree of muscle 
damage is unaffected.22,23  Nieman et al.2 reported that NSAID users did not have reduced race 
times, muscle damage or DOMS, while Friden and Lieber6 reported that administration of 
NSAID after eccentric exercise resulted in a short term benefit of pain relief, but a long term 
detrimental effect on muscle adaptation, inhibiting protein synthesis by suppressing the 
inflammatory reaction.  Paulsen et al.23 also indicated that although NSAID inhibited 
prostaglandin synthesis and local and systemic responses, it did not affect actual markers of 
muscle damage.  In this study, there was however no statistical difference in the measured 
markers of muscle damage or inflammatory response between NSAID users and non-users. 
 
Dehydration, intestinal temperature (Tintest), HR and evidence of muscle damage 
Although some athletes in our study experienced up to 4% body mass loss and others, on 
occasion, raced at a HR of more than 100% APmax (Table 5), these athletes did not present 
with clinical signs of dehydration, severe hyperthermia or increased muscle damage as 
reflected by changes in sOsm, Tintest > 40 º C or changes in serum CPK concentration, 
respectively. 
 
As the statistically significant (p≤0.05) inverse correlation between % change in body mass 
and post-pre change in sOsm was low (r=-0.365), sOsm, widely reported golden marker of 
hydration status,24 was used to quantitate changes in hydration status.  
 
The correlation between hydration status and systemic markers of muscle damage, as reflected 
by stage– induced changes in sOsm and serum CPK concentrations, although  statistically 
significant, was low. Hence it cannot be concluded from the 51 sets of paired data reported in 
this study, that hydration status has an overriding effect on systemic markers of muscle 





In the 12 individuals in whom continuous recordings of Tintest were recorded (Table 5), the 
correlation between race induced changes in Tintest and systemic markers of muscle damage, 
was also low and statistically insignificant. The data provided in this study, although, based on 
a relatively small sample size, therefore does not provide any support for the suggestion that 
rises in core body temperature, exacerbate muscle damage.   
 
Conclusion   
The relatively low post-race concentrations of systemic and urinary markers of muscle damage 
and inflammation,5 when compared to those reported following road running events of similar 
duration,16 are attributed to softer underfoot surfaces, large fluctuations in pace of running, and 
varied muscle recruitment patterns over the widely differing terrains.1 The sporadic increases 
in  intensity of effort, rises in Tintest, substantial body mass loss and increases in serum 
osmolality during the event, did not confirm previous suggestions3,4,11 that thermal and 
hydration status is directly related to the degree of muscle damage.  
 
It would be of interest to the investigate the impact of pre-race preparation on markers of 
muscle damage and inflammatory response found following this multi-day trail running event 
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Aim: To examine the effect of statin therapy, combined with a lipid uptake inhibitor, on 
markers of muscle damage and inflammation during trail running 
 
Setting: Three Cranes Challenge Trail run, in Karkloof, KwaZulu-Natal, South Africa 
 
Participant: A trained female endurance athlete currently being treated for familial 
hypercholesterolaemia with 20 mg Aspavor and 10 mg Ezetrol daily  
 
Independent Variables: 3-day 95 km trail run 
 
Main Outcome Measures: Changes in heart rate, body mass, blood neutrophil, serum creatine 
phosphokinase (CPK), high sensitivity C-Reactive Protein (hsCRP), cortisol, urinary 
myoglobin concentration (uMb), osmolality (UOsm) and specific gravity (USG)  
 
Results:   Maximum post stage serum CPK (665U/L), hsCRP (1.9mg/Ll) and cortisol 
(845nmol/L) concentrations corresponded with undetected uMb despite a maximum body mass 
loss of 4.5% 
  
Conclusions:   0.4 mg/kg Atorvastatin daily in combination with 10mg Ezetrol did not result 
in subjective myalgia, cramps, fatigue or increased markers of muscle damage following 
participation in the trail run 
 







The metabolic and cardiovascular benefits of regular prolonged exercise and the use of lipid 
lowering medication for patients with hypercholesterolaemia are undisputed (1).   However, 
the use of 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors or 
statins, the primary lipid-lowering medication currently prescribed for hypercholesterolaemia, 
and Ezetrol, a lipid uptake inhibitor, have been associated with muscle cramping, myalgia, 
fatigue and  in rare cases, rhabdomyoloysis and death (2,3,7,10,11).  According to the latest 
U.S. Food And Drug Administration (FDA) Safety Announcement, the highest approved dose 
of simvastatin is limited to 80mg per day due to the risk of muscle damage (7,10).  
 
Potential mechanisms to which side effects of chronic statin treatment in muscle have been 
attributed include intracellular depletion of essential metabolites and destabilization of cell 
membranes, resulting in (i) increased cytotoxicity (ii) the  deficiency of isoprenoids which 
participate in electron transport during mitochondrial oxidative phosphorylation and (iii) 
alterations in calcium shuttling, causing calcium leakage from the mitochondria and 
impairment of  sarcoplasmic reticulum calcium cycling and (iv) interactions with the hepatic 
cytochrome P-450 drug-metabolizing system (3, 7,10,11).   
 
The purpose of this study is to investigate muscle damage and inflammation during a multiday 
trail run on an athlete using a statin and a lipid-uptake inhibitor.  It is hypothesized that the 
muscle damage and inflammation of this athlete will be augmented above the mean of the 
study group (n=19) during the race and that she will experience fatigue and cramping which 
might be augmented by concomitant dehydration. Whether simultaneous intake of Ezetrol 
which has also been related to muscle damage, exacerbates this negative effect on muscle 
tissue in an endurance athlete, is however unknown.                             
 
Case Description 
Written informed consent was obtained from a female provincial cross-country athlete, aged 42 
years (height, 1.63cm; mass, 54.8kg;  body mass index (BMI), 20.63kg/cm2;   % body fat, 
25.3%;   blood pressure (BP), 122/80 mmHg), who was monitored during the Three Cranes 




age and her total cholesterol pre-medication was  > 9mmol/l. Her current daily prescription 
includes 20 mg Aspavor (containing Atorvastatin) and 10 mg Ezetrol.  Her training distance of 
an average of 60km/wk includes a high intensity session on hills, one on the track and one time 
trial per week. She has experienced chronic/recurring tendinosis of the right adductor muscles 
during the past 2 years. 
 
The Three Cranes Challenge is a 3-day trail run in South Africa over 95 km, 29.3, 37.9 and 
27.8 kilometers (km) during Stage 1 (S1), Stage 2 (S2) and Stage 3 (S3), with elevation gains 
of 1020, 1226 and 680m respectively. Ambient temperature and relative humidity ranged 
between 11.5 and 22.8 º C and 54 – 97%. The running surface varied from dual jeep track, 
gravel roads, grassland to single track through forests, over rocks, roots and streams. 
 
Venous blood and a urine sample were taken immediately before and after each stage and at 24 
and 72 hours post-race (PR).  At these time points, body mass and thigh circumference (TC) 
were also measured. A subjective rating of delayed muscle soreness (DOMS) was recorded 
before and after each stage as well as on Days 1-5 following the event. 
 
A commercial pathology laboratory conducted full blood counts on the venous blood samples, 
which were also analysed for  serum creatine phosphokinase(CPK), high sensitivity C-reactive 
protein (hsCRP), cortisol and osmolality (sOsm). Urine was analysed for myoglobin (uMb) 
content as well as osmolality (UOsm) and specific gravity (USG). Heart Rate (HR) was 
recorded throughout each stage using a polar monitor (Polar Electro OY, Finland)  
 
Results 
As shown in Table 1, running speed averaged 7:41, 7:33 and 6.17 min/km and heart rate (HR), 
131, 98 and 141 beats per minute (bpm), the equivalent of 74, 55 and 79% age predicted 
maximum (APmax)HR  during the 3 stages respectively. A representation of her continuous 
HR recordings in relation to the topographical characteristics of the routes for the different 






Table 1:  Race Performance and Mean, Maximum and Minimum Heart Rate Responses 
Max: maximum;  Min: minimum; *APMax = Age Predicted maximum (220-age) 
 
Figure 1:  Continuous heart rate recordings and topographical characteristics of the routes 
 
  









Min  Max  % AP 
Max* 
Mean Mean %  
AP Max 
ONE 29.3 03:57:13 
 
7:41 100 166 93 131 74 
TWO 37.9 05:07:43 7:33 60 162 91 98 55 




Table 2:  Haematological analyses and markers of muscle damage, inflammation and hydration status 
 
RBC: Red blood cell;  Hb: Haemoglobin;  Hct: Haematocrit;  Serum CPK: Serum Creatine 
phosphokinase;  Serum hsCRP: Serum High sensitivity C-Reactive Protein;  TC:  Thigh circumference;  
DOMS: Delayed onset muscle soreness;  USG: Urine specific gravity;  *ND: not detected 
 
Her red blood cell and platelet indices reflected a healthy profile. Race-induced elevations in 
leukocyte and neutrophil concentrations were modest, remaining within reference range (Table 
2).  
 
Variable   PreS1 PostS1 PreS2 PostS2 PreS3 PostS3 24h 72h Reference 
range 
RBC( 10^12/l) 4.37 4.01 4.03 4.17 3.79 4.01 3.86 3.88 3.8 – 4.8  
Hb (g/dl) 14.1 12.9 13.3 13.3 11.9 12.8 12.3 12.5 12 – 15 
Hct (%) 42.8 39.1 39.2 40.9 37.5 39.9 38.4 40.4 36 – 46 
Platelet (10^9/L) 236  238 225 245 207 246 187 208 150 -450 
Leukocyte (10^9/L) 4.35 6.79 4.75 7.5 4.86 5.05 4.21 6.75 3.92– 9.88  
Neutrophil (10^9/L) 1.83 5.20 2.02 5.79 2.25 5.05 1.85 4.64 2.00 – 7.50  
Serum CPK (U/L) 134 215 269 478 470 665 391 140 39 – 308  
Urinary myoglobin 
(mcg/ml) 
  ND* ND* ND* ND* ND* ND* ND* ND* <1 
Serum hsCRP(mg/l) 0.2 - - - - 1.9 1.4 0.6 <1.0 
TC (cm) 49.5 47 49.5 49 49 49 49 49  
DOMS Score 0 4 4 7 5 5 2 0  
Serum Cortisol 
(nmol/l) 
845 617 846 943 755 670 - - 190 – 690  
Serum Osmolality 
(mOsm/kg) 




754 482 564 705 1005 802 - - 300 – 800  
USG 1.020 1.015 1.020 1.025 1.03 1.03 - - Dehydration 
> 1.025 




As shown in Table 2, pre-race serum CPK concentrations (134U/L) were within the reference 
range (39-308 U/L) and rose to a maximum of 665U/L following S3. No uMb was detected at 
any reading. Serum CRP concentration rose from 0.2 mg/l to 1.9 mg/l post race, although she 
reported DOMS ratings of 4/10, 7/10 and 5/10 respectively during the 3 days of racing and 
2/10 for 24h and 48h PR. Early morning pre-race serum cortisol concentration (845 nmol/l) 
rose to maximum of 943 nmol/l following S2. Post-stage TC did not increase.  
 
sOSm concentrations and USG were indicative of substantial dehydration after S2, during 
which she experienced nausea and an inability to ingest carbohydrates and fluids. The 
dehydration persisted until completion of the race and is confirmed by the body mass loss of 
4.5% during S2 (Table 2). 
  
Discussion  
Statins have been found to be the most effective medications for reducing elevated blood 
concentrations of low density lipoprotein cholesterol and are currently being prescribed to 
more patients in greater dosages (11).  Although statins have been shown to reduce chronic 
inflammation in patients with coronary artery diseases and cardiovascular related mortality (8),  
dose related ( ≥ 1.0mg/kg) statin myotoxicity (7),  has been found to have adverse effects on 
muscle which may affect performance in sport (2,3,7,10,11). 
 
Seachrist et al. (10) reported that 78 % of professional athletes with familial 
hypercholesterolaemia could not tolerate statin therapy due to muscular problems and 
predisposing risk factors include being female, advancing age and the use of concurrent 
medications (2).   It was therefore of interest to observe how this female athlete, aged 42 years, 
ingesting a dose of  20mg/52 kg Aspavor combined with 10 mg Ezetrol per day, would respond 
to participation in a three-day 95 km trail run. 
  
Atorvastatin and simvastatin are lipophilic statins which promote ease of diffusion through 
passive transport across the bilipid cell membrane, causing augmented toxic effects on muscle 
at a dosage of >80mg/day (2,8).  At 0.5mg/kg, Seachrist et al. (10) demonstrated changes to the 




changes to the myofibre.  At doses of  ≥1mg/kg/day significant alterations in the myofibre and 
increases in serum CPK, alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
and plasma lactate were reported which were greater in Type II glycolytic fibres than in Type I 
muscle fibres. They concluded that ≥1mg/kg/day might promote statin-induced muscle damage 
and subsequent muscle mass loss. 
  
As athletes regularly present with CPK values in the “thousands” following ultradistance road 
running events (4,6), this subject’s accumulative CPK concentrations following the  three 
stages of the event indicate very little exercise-induced muscle damage. Her training status, a 
repeated bout effect and reduced muscle damage resulting from the inclusion of hill training in 
her program, might, together with  genetic factors and the dosage of her medication (0.4 
mg/kg), have contributed to her lower  serum CPK  concentrations (5).     
 
According to her HR data (Figure 1, Table 1), the greatest effort was during S3 although 
during all three stages her HR sporadically reached a maximum of over 90% APmax.  This 
indicates a moderate intensity of prolonged effort during S1 and S3.  The reduced intensity 
during S2 (Figure 1, Table 1), was probably due to her reported nausea and vomiting and 
evident dehydration (Table 2), which could have reduced muscle damage, resulting in an 
attenuated serum CPK concentration and the absence of uMb throughout the race.  This is also 
confirmed by her post-race concentration of serum hsCRP, 1.9 mg/l, which is indicative of 
only mild inflammation due to muscle damage, when compared to the mean concentration 
hsCRP in previous ultradistance events (6).  The anti-inflammatory effect of Atorvastatin (8) is 
likely to be a factor responsible for this attenuation.   
 
Her decreased thigh circumference after S1 (49.5cm – 47cm) may not be muscle mass loss due 
to statin therapy, but rather confirm previous findings (4) at the 2006 Isarrun, a 5-stage 338 km 
ultra- endurance run, where athletes experienced significant losses in skeletal muscle mass 
(particularly after S1), but not body mass during the race. 
 
Although her pre stage serum cortisol concentrations were above the reference range (Table 2), 




linked to her reported inability to ingest carbohydrates during this stage.  However, it did not 
affect her muscle damage during that stage (Table 2).  Post S1 and S3 serum cortisol 
concentrations indicated that she was running comfortably within her physiological range.   
 
Pre race sOsm indicates that she started the race adequately hydrated.  In view of the reported 
effect of dehydration on exercise-induced muscle damage (4) it is interesting to note that 
despite dehydration occurring during S2 and S3, as indicated by the substantial increases in  
sOsm,UOsm and USG and a body mass loss of 4.5% during S2, there was no excessive 
increase in the markers of muscle damage and inflammation (Table2). 
 
Although her pre-race RBC, Hb and HCT values reflect the absence of anaemia, the slight drop 
in RBC indices over the 3-day period may be due to transient osmotic stress, membrane lipid 
peroxidation caused by free radicals released by leucocytes, or even intramuscular destruction 
of RBC (9), which returned to normal within 72 hours post race.  The anti-inflammatory effect 
of Atorvastatin (8) probably contributed to the attenuation of the typical increase in leukocyte 
count during intense prolonged exercise, indicating an increase in metabolic activity and 
activation of neutrophil release (4, 5, 6).  
 
In conclusion we report that this subject, despite presenting with evidence of dehydration after 
S2 and S3, experienced no symptoms of statin- induced myalgia, fatigue or cramps during the 
3-day trail run. The adverse effects of Atorvastatin, combined with simultaneous intake of 
Ezetrol, were not evident at 0.4mg/kg.  Although the nausea experienced may have been an 
adverse effect, the fact that it only occurred during the more challenging strenuous S2, points 
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This study set out to determine the effect of multiday trail running on systemic and urinary 
markers of muscle damage and inflammation and the relationship with factors affecting muscle 
damage and inflammation during this endurance event.  The findings of this thesis reflect that 
i. the eccentric component of skeletal muscle contraction, when compared to road 
running events of similar duration, was not augmented during the three days of trail 
running 
ii. low markers of muscle damage and inflammation were recorded despite the 
maintenance of a mean intensity of effort of 77-84% APmax and the evidence of 
hyperthermia and dehydration, which have previously been found to augment exercise 
induced muscle damage and inflammation   
iii. markers of rhabdomyolysis and cardiac muscle damage were absent 
iv. the attenuated skeletal muscle damage and inflammation was confirmed by the small 
changes in DOMS and TC, which returned to baseline values by 72PR. 
 
It is concluded that the reduced muscle damage and inflammation are attributed to the softer 
surface underfoot and the technical difficulty of the terrain, which forced athletes to employ 
varied muscle recruitment patterns and to reduce their pace while maintaining a moderately 
high level of intensity.  It is therefore possible that trail running, although it involves a greater 
element of danger and hence greater predisposition to acute injuries, is less damaging than road 
running in terms of intrinsic exercise-induced skeletal muscle damage. 
 
The systemic and urinary evidence of muscle damage and inflammation in the case study was 
also attenuated and, in contrast to our hypothesis, she did not experience either muscle cramps 




been associated with muscle cramping, myalgia, fatigue and in rare cases, rhabdomyoloysis 
and death.   
 
It is thus suggested that the lower dosage of medication benefits this hypercholesterolaemic 
athlete, allowing her to participate in sport without experiencing the adverse events associated 
with higher dosages of the prescribed medication.  
 
In conclusion it is however important to highlight the limitations of this study.  These include  
i. the use of a limited convenience sample from whom full compliance was obtained, 
which may not have been representative of the population,  
ii. financial constraints limiting the number of tests performed and  
iii. lack of more comprehensive monitoring of the activity levels of the subjects during the 
post-stage recovery period.   
 
 
5.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
 
Directions for further research include  
i. investigating the difference in skeletal muscle damage and inflammation between 
multi-day road and trail running, using the same athletes whilst controlling variables 
such as their intensity of effort, nutrition, hydration and the activities of the athletes 
during the events and replicating the elevations of the routes, to match road and trail 
running routes. This would include exploring the difference in the extent and duration 
of fatigue experienced after multiday trail running events compared to road running; 
ii. investigating the hormonal control of fluid balance during multiday trail running 
events; 
iii. investigating the changes in cardiac structure and function during multiday events and 





Further research investigating the effects of the administration of different dosages of 
Atorvastatin with or without the use of Ezetimibe in double blind randomly selected placebo-
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THREE-CRANES TRAIL RUN 2011 
Study Title: Physiological assessment of participants in a three day trail run 





Thank you very much for agreeing to take part in the above trial. Although the final research 
papers are not yet published, we are happy to provide you with your results.   
 
Your Physical Characteristics 
 
 Your value Predicted norm for active 
non-athlete of your age, 
gender and BMI 
Height (m) 1.78  
Mass (kg) 80.1 
 
 
BMI 25.28 19 – 26 
Triceps skin fold (mm) 17.0  
Biceps skin fold (mm) 8.0  
Sub scapular skin fold (mm) 9.67  
Suprailliac skin fold (mm) 12.13  
Body Fat % (determined from triceps, 




11-17% (athletes 5 – 12%) 
Blood Pressure (mmHg)– Baseline 127/70 120/80 
Heart Rate (bpm)– Baseline 53 65 
 
Your BMI and resting blood pressure and heart rate fall within normal for a male athlete of 
your caliber, though your body fat % is higher than the norm. Enclosed are charts which you 





Body Fat Percentage for The Average Population 
Age Up to 30 30-50 50+ 
Females 14 - 21% 15-23% 16-25% 
Males 9-15% 11-17% 12-19% 
 
Average Body Fat Percentage of Athletes 




12-18% Rowing 6-14% 12-18% 








Cycling 5-15% 15-20% Sprinters 8-10% 12-20% 








Gymnastics 5-12% 10-16% Triathlon 5-12% 10-15% 




Ice/field Hockey 8-15% 12-18% Weightlifters 9-16% No data 
Racquetball 8-13% 15-22% Wrestlers 5-16% No data 





















1 11.5 - 21.7 0 - 2.3 63- 95  895.2 - 896.1 
2 12.4 - 22.8 0 - 2.8 54- 97  896.5 - 897.7 
3 12.1 - 21.2 0 - 2.3 64- 96  896.8 - 897.9 
 
 
Elevation gains and losses 
Running speed varied depending on topography of the routes. elevation gains reached 1020, 
1226 and 680m, while elevation losses were recorded at 1021, 1231 and 687m during Stages 






Running speed, heart rate and core body (intestinal) temperature 
 










ONE 32                     03:25:14 6:41 
TWO 42 04:23:47  
 
6.28 




Although the terrain was more technical during  Stage 2, your average speed was higher than 
Stage 1 and increased even more to 4:96 min/km during Stage 3.  
 
Topographical characteristics of Stage 1 


























Heart Rate Temperature  
 
As is shown above, your mean heart rates and temperate changes averaged over five-minute 
time-periods during Stage 1. In the first five minutes of the race, your heart rate already 
reached 145 bpm after and after which there were two substantial rises (over five minute 




interesting to relate the data in the two above figures noting the correlations between elevation 
gain/loss and heart rate – temperature response. 
 




Max % AP 
Max 





     
164 88 136 153 82 
Day 2 165 88 107 149 80 
Day 3 180 96 127 155 83 
 
You maintained a high intensity heart rate of between 80 and 83% of age predicted maximum 
during all three stages, reflecting your experience in multiday trail running events.  
 
Core Body Temperature changes during stage 1 
 Maximum Minimum Mean Median Mode 
DAY 1 39.4 37.3 38.7 38.8 39.0 
  
Your maximum body temperature appears to have been reached about  55-60 minutes into the 
stage. This is relatively high, but well below the cut- off point of  > 40.5 º C for heat related 
injury and heat stroke. 
 
Blood/Urine Tests and Related Results  
 
1. Serum Creatine Phosphokinase and urinary myoglobin  
Serum CPK concentration is commonly used as a systemic marker of exercise-induced skeletal 
muscle damage. It leaks into the blood when the membrane surrounding muscle cells is 
damaged. 
 
Your CPK concentration in the blood on the morning of the race was 269U/L which falls 
within the norm of 39-308 U/L showing that you started the race without evidence of muscle 
damage.  
 
Serum CPK concentration is known to peak 24 hours post exercise. Before Stage 2 (Pre S2) 
your serum CPK concentration was 746U/L (reference range 39-308 U/L), indicating that some 
muscle damage occurred during stage 1.  Your serum CPK concentration reached its maximum 
for this race, 1562U/L at the post S3 reading. As athletes present with values in the 
“thousands” following a road running event such as Comrades, your accumulative CPK values 
over the 3 days, however, only indicate mild exercise-induced muscle damage. 
 
For example, you may be interested that following the 166km North Face Ultra Trail du Mont 
Blanc mountain marathon (2009) with only 9500m of positive and negative elevation change, 





Remembering that training status and the inclusion of hill training in your programme results 
in a repeated bout training effect and reduced muscle damage, your result is very encouraging 
as you are showing far less muscle damage than these European athletes.   
 
Most of the athletes who attended the 72 h post race testing session recorded serum CPK 
concentrations similar to pre-race levels, indicating no further leakage of this muscle enzyme 
into the blood. A pity that you missed these sampling stages.  
 
 
Serum Creatine Phosphokinase (U/L) 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 24h 72h Reference range 
269 537 746 1193 1069 1562 - - 39-308 U/L 
 
Interestingly these results are confirmed by your urinary myoglobin levels which were within 
the normal range again reflecting the absence of severe muscle damage. 
 
 
2. High Sensitivity C-Reactive Protein and other evidence of muscle inflammation 
C-Reactive Protein is a systemic marker of inflammation and acute phase response to muscle 
damage. Although it often used as an indicator for chronic cardiovascular disease when raised 
in a resting state, we have used it as a marker of delayed inflammatory response to exercise-
induced muscle damage in this study. 
 
Your resting hs-CRP concentration was 0.8mg/l which represents both a low cardiovascular 
disease risk (according to American Heart Association guidelines) and indicates the absence of 
muscle inflammation pre-race. In the North Face Ultra Trail mountain marathon, mean 
concentration measured was 37.7 mg/l and in our lab we have recorded mean 24 hour post-race 
values of almost 40 mg/l in two studies completed on the Comrades downrun.   
 
Hs-CRP (mg/l) 
Pre S1 Post S3 24h 72h Reference 
0.8 
 
14.5 - - <1.0mg/l = low risk 
 
Correlating with the above-mentioned  indications of mild muscle damage incurred during the 
event,  is your post S3 concentration shown in the above table.   
 
It is a pity that you were not able to provide post-race blood samples. Most athletes recorded 
reduced values at 24 and 72 h post race, representing a normal reduction in inflammation post-




















59 54.5 59 59 57 58 59 57.6 
 
A study  by Knechtle and Kohler  (2007) conducted on the 2006 Isarrun, a 5-stage 338 km 
ultra- endurance run in Bavaria, Germany,  revealed that athletes experienced significant losses 
in skeletal body mass ( particularly after Stage 1 of the race), but not body mass during the 
race. Your decreased thigh circumference after Stage 1 therefore may well confirm these 
findings.  
 
The return to pre-race circumference within 4 hours post race confirms an inflammatory 
response which follows mild degrees of swelling and accumulation of fluid within the 
interstitial spaces between the active muscles.   
 
 
3. Serum Cortisol concentration 
Cortisol is a hormone secreted by the adrenal glands and is often elevated in times of physical 
or mental stress. Cortisol increases the glucose available to the muscles by stimulating the 
breakdown of glycogen and also acts as a powerful anti-inflammatory hormone. Cortisol 
secretion in the body normally follows a diurnal pattern, being highest between 5 – 10am and 
lowest between 8pm – 4am.  In the case of athletes running a race, blood cortisol 
concentrations may also be elevated in the morning due to anticipation or hyperglycaemia, but 
do tend to increase further during prolonged exercise. 
 
Your cortisol result for the morning of the first day was 711nmol/l which is higher than the 
norm, probably due to anticipatory anxiety.  Usually during a race the cortisol values increase 
due to physiological stress.  As shown in the table below, the metabolic demands/ anti-
inflammatory response appear to have been increased during Stage 2 and greatest during Stage 
3, confirming your increased average heart rate and speed maintained during Stage 3. 
 
Serum Cortisol concentration (nmol/l) 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 Reference 





4. Phadiatop and Immunoglobulin E 
These blood tests are used to diagnose and monitor allergy reactions. The Phadiatop test  
shows whether you are allergic to a range of common inhalant allergens, including animal 





Your Phadiatop test result was 2.08 IU/ml. As the reference values for this test are 0.00-0.35 
IU/ml, this is positive for inhaled allergens, signifying a degree of sensitivity to an airborne 
allergen.  
 
However, your IgE concentrations during the race ranged between 42.8 and 62 IU/ml which 
are within the normal range (0.0-100.0 IU/ml), indicating that the specific allergen to which 
you are sensitive, was not present during the race.   
 
Serum IgE concentration 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 24h 72h Reference range 
42.8 49.7 49.4 46.8 62 58.2 - - 0 – 100 IU/ml 
 
 
6.  Full blood Count 
The full blood count (also known as differential blood count) measures the concentrations of 
various blood cells (red blood cells, white blood cells and platelets) and may give an indication 
of general health status and point to the presence of  inflammation, allergy or infection.  
 
The full blood count is also used to diagnose anaemia by reflecting haemoglobin 
concentrations. 
 
Tabulated below are your readings of red blood cell indices during and after the race: 
 
 
Red blood cell ( RBC) count (10^12/l) 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 24h 72h Reference range 
5.21 5.16 4.86 5.22 4.89 4.93 - - 4.5 – 5.5 10^12/l 
 
Haemoglobin (Hb) (g/dl) 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 24h 72h Reference range 
15.3 15.1 14.4 15.5 14.3 14.6 - - 13 - 17g/dl 
 
Haematocrit (Hct) (%) 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 24h 72h Reference range 
44.4 44.1 41.7 44.2 42.8 42.5 - - 40 - 50% 
 
Your initial/pre-race RBC, HB  and Hct values reflect the absence of anaemia and a  healthy 
red blood cell status for a male distance runner. Well done! 
 
The slight drop during the race may be due to a possible shift of the fluid from the interstitial 
fluid into the blood. This is nothing to worry about as it corrected itself post race.   
 
The slight drop in RBC, Hb and Hct concentration experienced during the latter part of the 
three-day race may also confirm a small degree of “foot strike haemolysis”, that is to be 





At rest, your platelet count was 301 10^9/L and total white blood cell count was 7.58 10^9/L.  
These parameters, including your differential white blood cell count, were within normal limits 
 
After every stage there was an increase in the white blood cell count, which is the expected  
normal physiological and inflammatory response to this type of exercise.  Results are given in 
the table below. 
 
White blood cell count (10^9/L) 
Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 24h 72h Reference range 




With regard to the URTI symptoms that you experienced before and after the race, we can 
conclude from the results of the blood analyses conducted that  
(1) there was no indication of allergic origin 
(2) there was no indication of a viral infection  
(3) the elevated CRP, WBC and neutrophil concentrations confirm the possibility of    
a mild  inflammatory response to a bacterial infection 
  
5.  Hydration status changes: Serum and Urine Osmolality, Urine Specific Gravity and 
Body  Mass 
 
Serum osmolality is the golden marker of hydration status during endurance events. 
 
The values shown in the table below indicate that you started the race slightly underhydrated 
with a more concentrated urine with higher osmolality than advisable. The serum osmolality  
increased after S1 indicating that you underhydrated during Stage 1. It returned to within 
normal values pre Stage 2 and 3, indicating adequate hydration overnight, although it again 
increased to levels above the laboratory reference range during Stage 2 and 3, reflecting a 
pattern of dehydration during the race, which might be detrimental to your performance. 
 
 
Test   Pre S1 Post S1 Pre S2 Post S2 Pre S3 Post S3 Reference range 
S Osmol 284 297 288 301 290 298 275 – 295mOsm/kg 
U Osmol 1029 801 774 924 1176 990 300 – 800mOsm/kg 




Urine osmolality and specific gravity values provide a somewhat delayed indication of  
hydration status following kidney filtration processes. 
 
Interestingly, your urine osmolality was particularly high at the start of  Stages 1and 3, 




resulted in the high values throughout the race and might have affected your running 
performance. 
 
The above is confirmed by the changes in urine specific gravity (USG). A urine specific 
gravity of 1.010 is indicative of a well hydrated state. At no stage was your USG at that level. 
 
The changes in body mass also reflect some degree of fluid loss, although recent research 
(Nolte, 2010) has, however, confirmed that changes in body mass cannot be used as accurate 
surrogate for changes in total body water during prolonged exercise.  
 
Body mass (kg) 
Pre S1 Post S1 % loss Pre S2 Post S2 % loss Pre S3 Post S3 %loss 
79.68 77.5 2.7 79.86 76.95 3.6 79.74 78.04 2.1 
 
 
We do hope that these findings are of interest to you and would once again like to thank you 
for being such a reliable research subject during the 3 days of racing. 
 
 





Prof E Peters-Futre                                              
Research Director 
 
Dr. Rentia Denissen 
Dr. Anton de Waard                                                             
Mr Navin Singh 
Masters in Medical Science:                                               

















DEPARTMENT OF HUMAN PHYSIOLOGY 





                    SUBJECT INFORMATION FORM 
 
 
Study title:  Physiological assessment of runners participating in three-day trail run 






This study has received ethics approval from the University of KwaZulu-Natal, Nelson R Mandela 
School of Medicine, Research Ethics Committee (Reference No: BF210/010) 
 
Study Aims: 
The primary questions to be examined in this study are to include the following:  
 
Whether amateur athletes competing in a multistage mountain trail run  
(1) incur muscle damage  
(2) are adequately, over or under hydrated and  
(3) experience an increased incidence of Upper Respiratory Tract Infections due to 
airborne allergic responses 
  
 
Who will qualify to participate in this study?   
 1.  Healthy athletes (not in possession of CVS, renal, hepatic or endocrine dysfunction) 
between the ages of 25 and 50 years taking part in the 2010 3-Cranes Mountain Trail Run on 
25-27 February 2010. 
 2.  Residents in the greater eThekweni and Umzumduzi area. 
 3.  Those willing to take part in the study and consent for all aspects of test e.g. regular  
 blood tests, provision of saliva and urine samples, skin prick tests, weighing, filling in 
questionnaires, measuring urine output. 
 
What will be expected from volunteers in this study?  
You will be asked to: 




 2. Maintain your normal diet throughout the study. 
 
Outline of tests: 
Pre race Briefing – Day before race – REGISTRATION: 24 February 2011 
1. Complete a medical questionnaire and undergo a full medical exam if indicated. 
2. Complete a pre-race questionnaire concerning your training experience as well as details 
about the fluids you consume when exercising  
3. Assessment of height, mass and percentage body fat (to be estimated from  skinfold 
thicknesses). 
 
During race (before and after each stage)– Research station at Karkloof 
1. Body mass measurement. 
2. Three vials (approx 9-12 ml) of blood to be taken before and after the event. 
3. Provide a urine sample 
4. Complete a brief questionnaire. 
5. Record all fluid consumed and all urine output during stage and overnight. 
6. Wear a heart rate monitor throughout the race   
 
24, 48 and 72 Hours after race - Exercise Laboratory, Physiology Department, E2 
Building  
1. Body mass measurement. 
2. Three vials of blood (approx 9-12 ml) to be taken. 
3  Provide a urine and saliva sample. 
4. Complete a brief questionnaire       . 
 
How can you benefit from participation in this study?  
Following the study, you will be given the results of your full blood counts and other 
biochemical/ laboratory tests which were run on your blood samples. As soon as the data has 
been collated, you will receive the study results.   
A furthering of knowledge regarding your fluid balance during endurance exercise as well as 
hydration status will be gained from this work.  This will allow you to optimize your fluid use 
in the future and improve your performance.  You will be the first to be notified of the results 
of this study. 
 
Will you be exposed to adverse effects of the study? 
There will be minimal risks to you by being involved in the study.  Some people find 
venipuncture (taking blood) uncomfortable.  There is a very slight risk of complications from 
this procedure, mainly infection at the site of puncture or inflammation (swelling) of the vein 
used.  In the unlikely event of a complication occurring, it is not likely to prevent you from 
completing the event.  A n experienced qualified nurse will be taking the samples.  She will do 
my best to prevent complications by ensuring procedures are performed according to the same 
standards the subjects would experience in a hospital environment.  Both of the above 
mentioned complications are easily treated. 
 




As participation is entirely voluntary, you may withdraw from the study at any time without 
penalty.  
 
Will your individual results remain confidential?  
Yes.  The records identifying the participant will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly available. The 
study is for degree purposes however the results of the study may be published. In all cases the 
participant’s identity will remain confidential.  
 
Financial compensation. 
Any out-of-pocket expenses which you may incur as a result of your participation in this study 
(e.g. traveling expenses) will also be reimbursed by the research team. 
 
Further queries? 
Should you have any queries or wish to obtain further details regarding this study, please do 
not hesitate to contact us. 
             Prof Edith Peters-Futre – (031) 260-4237(w); 261-3869(h). 
             Study Director  
 
     Contact details of REC administrator and chair – for reporting of complaints / problems. 
     
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
University of KwaZulu-Natal  
Research Office, Westville Campus  
Govan Mbeki Building  
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  









DEPARTMENT OF PHYSIOLOGY 
COLLEGE OF HEALTH SCIENCES 
 
 
Physiological assessment of participants in a three-day trail run event:  markers of 
muscle   damage,   hydration and immune status. 
 
 
                                                         SUBJECT CONSENT FORM 
 
I, ………………………………………….. hereby agree to participate in a research study to be 
performed by Dr. Rentia Denissen, Dr Anton de Waard, Mr. Navin Runjit Singh and Professor 
Edith Peters-Futre in the Department of Human Physiology in the College of Health Sciences 
of the University of KwaZulu-Natal. I have been informed about the study by the principal 
investigator, Professor Peters-Futre.  
 
I understand that the basic procedures to be carried out are to include:  
1. Completion of URTI questionnaire for 14 days prior to the race  
2. Assessment of height, mass and percentage body fat, heart rate, blood pressure and peak 
flow prior to registration on 24 February 
3. Completing two questionnaires as well as providing a small vial of blood (2ml) to perform 
an allergy test at the pre-race briefing 
4. Completion of a brief questionnaire, giving a urine and saliva sample and the taking of three 
vials of blood (a total of no more than 14ml of blood), twice daily (before and after each stage 
of the three-day event) 
5. Completion of a post-stage questionnaire, giving a urine sample and three vials of blood 24, 
48 and 72 hrs after the race finishes 
6. Accurately measuring all fluid consumed and urine voided throughout the duration of the 
race, and recording the incidence of upper respiratory tract infection symptoms during the 2-
week post-race period 
7. Completion of a URTI questionnaire for 14 days following the race 
 
The details of these procedures have been explained to me in full. I am aware that a certain 
level of discomfort may occur when the blood is taken and that this procedure may be 
accompanied by certain medical risks including infection and inflammation of the vein.    
 
I understand that the study forms part of the Masters degrees of Drs Rentia Denissen and 
Anton de Waard and that the results may be published.  
 






I may contact the principal investigator of the project, Professor Peters Futre at 073- 7597974 
at any time if I have questions about the research or if I are injured as a result of the research. 
 
_________________                        ______________ 
Signature of Participant                                Date 
 
____________________                  __________________ 








                 
 
                                             DEPARTMENT OF PHYSIOLOGY 
                                           FACULTY OF HEALTH SCIENCE 
                                         




Physiological assessment of participants in a three-day trail run event:  markers 
of muscle damage. 
 
Name of Subject:………………...............................Number…………………             
 
 
SECTION A: PLEASE ANSWER ALL QUESTIONS.   
 
 
1.  Date of birth: ______________________        Age:___________     
     
 2.  Address: 
______________________________________________________________________ 
 








4. Running  club:  ________________________ 
 
5.  Occupation: ___________________________ 
 
 
Please tick one of the boxes in each of the following questions:  
 
 6.  How many hours do you generally run per week? 





□ <  5 
□ 6 - 10 
□ 11 - 15 



























11.   Average weekly running distance: ____________km 
12.   Running history 
 serious\social :_________________ 
          age started running: ___________________( ….yrs) 
          level of training during these years _________________________ 
          total number of running  races: __________________ 
 
13.   Describe the terrain used for training  
 
       ____________________________________________________________________ 
      (take into consideration – number of days on flat; on hills, distance on hills, track, etc)                        
 





□ WEEK-END WARRIOR (only run on weekends) 
□ SERIOUS AMATEUR (> 5 races per year) 
□ ELITE (regular top 10% finisher) 
□ PROFESSIONAL (paid to run) 
□ OTHER – SPECIFY…………………………. 
□ FUN RUNS 
□ < 5  x 21 km races)  PER YEAR 
□ < 5 marathons (42km)  PER YEAR 
□ > 2 ultra marathons (52 km or longer) PER YEAR 
□ PREVIOUS MULTISTAGE RACES e.g. Cape Odyssey, 3 Cranes 






15.  List races / competitions over the last 6 months (all sports)  
 
      __________________________________________________________ 
 




   17.  Personal best times in last 12 months:  
 
10 km  56 km  
21.1 km  90 km  
42.2 km  Other- specify  
 
 
Dietary and fluid intake details 
 




2.  Are you presently using any supplements? (Multivit, Calmag, etc) yes  no .  If yes, 




3.  Do you use water and/or a sports drink during the race? 
________________________________________________________________________ 
 







THANK YOU FOR YOUR PARTICIPATION 
 
 
____________________________              ___________________ 




_________________________________        ____________________ 








Height (cm): _________________ Mass (kg): __________________ 
 
Thigh circumference (cm) ____________________________________ 
 
Skin – fold Measurements: 
Biceps: ___________    ___________    ____________     __________ 
Triceps: ___________    ___________    ___________     __________ 
Suprailliac: __________    __________    __________     __________ 
Subscapular: _________    __________    ___________   __________ 
Body fat percentage: ___________________________________ 
 
Resting heart rate:           _________ /min   ______________/min 


























DEPARTMENT OF PHYSIOLOGY 
FACULTY OF HEALTH SCIENCE 
                                         
                                       THREE-CRANES RESEARCH PROJECT, 2011  
 
 
The effect of a multiday trail run on systemic markers of muscle damage 
 
POST RACE QUESTIONNAIRE: 
DELAYED ONSET MUSCLE SORENESS 
 
Please rate muscle pain on a scale of 0 – 5 where  
0 = no pain at all 
5 = very severe/maximal  
 
 QUADS HAMSTRINGS CALVES 
DAY 1 (after run)    
DAY 2    
DAY 3    
DAY 4    
















     




Dear Emmerentia Denissen, 
I have the pleasure to inform you that your paper "Low markers 
of muscle damage and inflammation following a three–day trail 
run" has been accepted for publication. The publishers will 
contact you within 3 weeks and ask you to check the proofs of 
your paper which will be published in issue 1, 2012. The PDF 
version of the paper will be available for downloading once the 
paper has been published.  
 











Professor Mike Lambert 
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